UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022.
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________.
Commission File Number: 001-38298
Zomedica Corp.
(Exact name of registrant as specified in its charter)
Alberta, Canada | ||
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification Number) |
100 Phoenix Drive, Suite 125 | 48108 | |
(Address of principal executive offices) | (Zip code) |
(734) 369-2555
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Shares, without par value | ZOM | NYSE American |
As of November 14, 2022, 979,949,668 shares of the registrant’s common shares, without par value, were issued and outstanding.
ZOMEDICA CORP.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED
September 30, 2022
TABLE OF CONTENTS
Page | ||
3 | ||
Management’s Discussion and Analysis of Financial Condition and Results of Operations | 24 | |
33 | ||
33 | ||
33 | ||
34 |
2
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements.
Zomedica Corp.
Consolidated balance sheets
(Unaudited) (United States dollars in thousands)
As of | ||||||
| September 30, |
| December 31, | |||
| 2022 |
| 2021 | |||
Assets |
|
|
|
| ||
Current assets |
|
|
|
| ||
Cash and cash equivalents | $ | 45,095 | $ | 194,952 | ||
Available-for-sale securities |
| 74,200 |
| — | ||
Trade receivables, net |
| 719 |
| 315 | ||
Inventory, net |
| 2,400 |
| 2,848 | ||
Prepaid expenses and deposits |
| 3,611 |
| 1,842 | ||
Other receivables |
| 1,078 |
| 450 | ||
Total current assets |
| 127,103 |
| 200,407 | ||
| ||||||
Prepaid expenses and deposits |
| 230 |
| 394 | ||
Property and equipment, net |
| 6,727 |
| 1,130 | ||
Construction in progress | 202 | 420 | ||||
Right-of-use asset |
| 1,567 |
| 1,320 | ||
Goodwill |
| 64,230 |
| 43,288 | ||
Intangible assets, net |
| 42,778 |
| 33,176 | ||
Non current available-for-sale securities |
| 39,197 |
| — | ||
Other assets |
| 265 |
| 265 | ||
Total assets | $ | 282,299 | $ | 280,400 | ||
| ||||||
Liabilities and shareholders’ equity |
|
|
|
| ||
| ||||||
Current liabilities |
|
|
|
| ||
Accounts payable and accrued liabilities | $ | 6,244 | $ | 3,225 | ||
Accrued income taxes |
| 41 |
| 240 | ||
Current portion of lease obligations |
| 578 |
| 415 | ||
Customer contract liabilities |
| 205 |
| 198 | ||
Other current liabilities |
| 58 |
| 262 | ||
Total current liabilities |
| 7,126 |
| 4,340 | ||
| ||||||
Lease obligations |
| 1,058 |
| 964 | ||
Deferred tax liabilities |
| 2,249 |
| 3,709 | ||
Customer contract liabilities |
| 213 |
| 140 | ||
Other liabilities |
| 2,872 |
| 361 | ||
Total liabilities | $ | 13,518 | $ | 9,514 | ||
Commitments and contingencies (Note 15) |
|
|
|
| ||
Shareholders’ equity |
|
|
|
| ||
Unlimited common shares, no par value; 979,949,668 and 979,899,668 and at September 30, 2022 and December 31, 2021 | $ | 380,973 | $ | 380,962 | ||
Additional paid-in capital |
| 22,227 |
| 9,313 | ||
Accumulated deficit |
| (133,597) |
| (119,391) | ||
Accumulated comprehensive (loss) |
| (822) |
| 2 | ||
Total shareholders' equity |
| 268,781 |
| 270,886 | ||
| ||||||
Total liabilities and shareholders’ equity | $ | 282,299 | $ | 280,400 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
Zomedica Corp.
Consolidated statements of loss and comprehensive loss
(Unaudited) (United States dollars in thousands, except per share data)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 | |||||
Net revenue | $ | 4,776 | $ | 23 | $ | 12,773 | $ | 52 | ||||
Cost of revenue |
| 1,215 |
| 18 |
| 3,415 |
| 59 | ||||
Gross profit (loss) |
| 3,561 |
| 5 |
| 9,358 |
| (7) | ||||
|
|
|
|
|
|
|
|
|
| |||
Expenses |
|
|
|
|
|
|
|
| ||||
Research and development |
| 1,131 |
| 289 |
| 1,801 |
| 1,008 | ||||
Selling, general and administrative |
| 9,022 |
| 6,124 |
| 24,344 |
| 14,594 | ||||
Loss from operations |
| (6,592) |
| (6,408) |
| (16,787) |
| (15,609) | ||||
Interest income |
| 1,012 |
| 94 |
| 1,396 |
| 262 | ||||
Loss on disposal of assets | — | (27) | (1) | (270) | ||||||||
Other income (loss) |
| (5) |
| 1 |
| (8) |
| 530 | ||||
Foreign exchange loss |
| (67) |
| (6) |
| (123) |
| (6) | ||||
Loss before income taxes |
| (5,652) |
| (6,346) |
| (15,523) |
| (15,093) | ||||
Income tax benefit |
| 657 |
| — |
| 1,317 |
| — | ||||
Net loss |
| (4,995) |
| (6,346) |
| (14,206) |
| (15,093) | ||||
Unrealized losses, change in fair value of available-for-sale securities, net of tax |
| (803) |
| — |
| (803) |
| — | ||||
Change in foreign currency translation |
| (32) |
| — |
| (21) |
| — | ||||
Net loss and comprehensive loss | $ | (5,830) | $ | (6,346) | $ | (15,030) | $ | (15,093) | ||||
|
| |||||||||||
Weighted average number of common shares - basic and diluted |
| 979,946,407 |
| 978,494,076 |
| 979,915,419 |
| 948,664,410 | ||||
| ||||||||||||
Loss per share - basic and diluted (Note 17) | $ | (0.005) | $ | (0.006) | $ | (0.014) | $ | (0.050) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Zomedica Corp.
Consolidated statements of shareholders’ equity
(Unaudited) (United States dollars in thousands)
| For the Nine Months Ended September 30, 2022 | |||||||||||||||||||
Common | Additional | Accumulated | ||||||||||||||||||
Common Stock | Stock | Paid-In | Accumulated | Comprehensive |
| |||||||||||||||
Shares |
| Amount |
| Subscribed | Capital |
| Deficit |
| (Loss) |
| Total | |||||||||
Balance at December 31, 2021 | 979,899,668 | $ | 380,962 | $ | - |
| $ | 9,313 | $ | (119,391) | $ | 2 | $ | 270,886 | ||||||
Stock-based compensation |
| — |
| — |
| — |
| 6,452 |
| — |
| — |
| 6,452 | ||||||
Warrants issued | — | — | — | 6,465 | — | — | 6,465 | |||||||||||||
Stock issuance from warrant exercises |
| 50,000 |
| 8 |
| — |
| — |
| — |
| — |
| 8 | ||||||
APIC reclass for warrants |
| — |
| 3 |
| — |
| (3) |
| — |
| — |
| — | ||||||
Net (loss) |
| — |
| — |
| — |
| — |
| (14,206) |
| — |
| (14,206) | ||||||
Other comprehensive (loss) |
| — |
| — |
| — |
| — |
| — |
| (824) |
| (824) | ||||||
Balance at September 30, 2022 |
| 979,949,668 | $ | 380,973 | $ | - | $ | 22,227 | $ | (133,597) |
| $ | (822) | $ | 268,781 |
| For the Three Months Ended September 30, 2022 | |||||||||||||||||||
Common | Additional | Accumulated | ||||||||||||||||||
Common Stock | Stock | Paid-In | Accumulated | Comprehensive |
| |||||||||||||||
Shares |
| Amount |
| Subscribed | Capital |
| Deficit |
| (Loss) |
| Total | |||||||||
Balance at June 30, 2022 | 979,899,668 | $ | 380,962 | $ | - |
| $ | 13,845 | $ | (128,602) | $ | 13 | $ | 266,218 | ||||||
Stock-based compensation |
| — |
| — |
| — |
| 1,920 |
| — |
| — |
| 1,920 | ||||||
Warrants issued | — | — | — | 6,465 | — | — | 6,465 | |||||||||||||
Stock issuance from warrant exercises |
| 50,000 |
| 8 |
| — |
| — |
| — |
| — |
| 8 | ||||||
APIC reclass for warrants |
| — |
| 3 |
| — |
| (3) |
| — |
| — |
| — | ||||||
Net (loss) |
| — |
| — |
| — |
| — |
| (4,995) |
| — |
| (4,995) | ||||||
Other comprehensive (loss) |
| — |
| — |
| — |
| — |
| — |
| (835) |
| (835) | ||||||
Balance at September 30, 2022 |
| 979,949,668 | $ | 380,973 | $ | - | $ | 22,227 | $ | (133,597) |
| $ | (822) | $ | 268,781 |
| For the Nine Months Ended September 30, 2021 | |||||||||||||||||||
Common | Additional | Accumulated | ||||||||||||||||||
Common Stock | Stock | Paid-In | Accumulated | Comprehensive |
| |||||||||||||||
Shares |
| Amount |
| Subscribed | Capital |
| Deficit |
| (Loss) |
| Total | |||||||||
Balance at December 31, 2020 | 642,036,228 | $ | 104,784 | $ | 460 |
| $ | 14,792 | $ | (68,969) | $ | - | $ | 51,067 | ||||||
Stock-based compensation |
| — |
| — |
| — |
| 4,503 |
| — |
| — |
| 4,503 | ||||||
Stock issuance from warrant exercises |
| 200,951,905 |
| 44,082 |
| (460) |
| (11,511) |
| — |
| — |
| 32,111 | ||||||
Stock issuance costs |
| — |
| (14,281) |
| — |
| — |
| — |
| — |
| (14,281) | ||||||
Stock issuance for financing |
| 105,013,158 |
| 199,525 |
| — |
| — |
| — |
| — |
| 199,525 | ||||||
Stock issuance from exercise of stock options |
| 7,017,776 |
| 2,819 |
| — |
| (1,051) |
| — |
| — |
| 1,768 | ||||||
Stock redemption |
| 24,719,101 |
| 44,000 |
| — |
| — |
| (32,039) |
| — |
| 11,961 | ||||||
Net (loss) |
| — |
| — |
| — |
| — |
| (15,093) |
| — |
| (15,093) | ||||||
Balance at September 30, 2021 |
| 979,738,168 | $ | 380,929 | $ | - | $ | 6,733 | $ | (116,101) |
| $ | - | $ | 271,561 |
| For the Three Months Ended September 30, 2021 | |||||||||||||||||||
Common | Additional | Accumulated | ||||||||||||||||||
Common Stock | Stock | Paid-In | Accumulated | Comprehensive |
| |||||||||||||||
Shares |
| Amount |
| Subscribed | Capital |
| Deficit |
| (Loss) |
| Total | |||||||||
Balance at June 30, 2021 | 977,950,993 | $ | 380,222 | $ | - |
| $ | 5,602 | $ | (109,755) | $ | — | $ | 276,069 | ||||||
Stock-based compensation |
| — |
| — |
| — |
| 1,438 |
| — |
| — |
| 1,438 | ||||||
Stock issuance from warrant exercises |
| — |
| — |
| — |
| — |
| — |
| — |
| — | ||||||
Stock issuance costs |
| — |
| — |
| — |
| — |
| — |
| — |
| — | ||||||
Stock issuance from exercise of stock options |
| 1,787,175 |
| 707 |
| — |
| (307) |
| — |
| — |
| 400 | ||||||
Net (loss) |
| — |
| — |
| — |
| — |
| (6,346) |
| — |
| (6,346) | ||||||
Balance at September 30, 2021 |
| 979,738,168 | $ | 380,929 | $ | — | $ | 6,733 | $ | (116,101) |
| $ | — | $ | 271,561 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
Zomedica Corp.
Condensed consolidated statements of cash flows
(Unaudited) (United States dollars in thousands)
| For the Nine Months Ended September 30, | |||||
| 2022 |
| 2021 | |||
Cash flows from operating activities: |
|
|
|
| ||
Net loss | $ | (14,206) | $ | (15,093) | ||
Adjustments for |
|
|
|
| ||
Depreciation |
| 270 |
| 175 | ||
Amortization - intangible assets |
| 2,540 |
| 136 | ||
Loss on disposal of property and equipment |
| 1 |
| 248 | ||
Loss on other assets |
| — |
| 5 | ||
(Gain) loss on right-of-use assets |
| — |
| (533) | ||
Stock-based compensation |
| 6,452 |
| 4,503 | ||
Non cash portion of rent expense |
| 9 |
| 36 | ||
Accretion/amortization of available-for-sale securities |
| (400) |
| — | ||
Change in non-cash operating working capital, net of acquisitions |
|
| ||||
Purchased inventory |
| (3,637) |
| (1,875) | ||
Prepaid expenses and deposits |
| (1,330) |
| (61) | ||
Trade receivables |
| (442) |
| (7) | ||
Other receivables |
| 69 |
| (123) | ||
Accounts payable and accrued liabilities |
| 3,020 |
| 3,216 | ||
Accrued income tax |
| (199) |
| — | ||
Deferred tax liabilities |
| (1,319) |
| — | ||
Other current liabilities |
| (204) |
| — | ||
Customer contract liabilities |
| 81 |
| — | ||
Other liabilities |
| 8 |
| — | ||
Net cash used in operating activities |
| (9,287) |
| (9,373) | ||
Cash flows from investing activities: |
|
|
|
| ||
Investment in securities |
| (113,225) |
| — | ||
Investment in debt security (at fair value) |
| (1,000) |
| — | ||
Investment in property and equipment |
| (583) |
| (97) | ||
Acquisition of intangibles |
| (143) |
| (246) | ||
Investment in construction in progress | (1,274) | — | ||||
Investment in assets purchased (Assisi and Revo) | (24,304) | — | ||||
Net cash used in investing activities |
| (140,529) |
| (343) | ||
Cash flows from financing activities: |
|
|
|
| ||
Cash proceeds from issuance of common shares and warrants |
| — |
| 199,525 | ||
Cash received from warrant exercises |
| 8 |
| 32,112 | ||
Cash paid for shares and warrant issuance costs |
| — |
| (14,269) | ||
Cash received from stock option exercises |
| — |
| 1,768 | ||
Net cash provided by financing activities |
| 8 |
| 219,136 | ||
(Decrease) increase in cash and cash equivalents |
| (149,808) |
| 209,420 | ||
Effect of exchange rate changes on cash | (49) | — | ||||
Cash and cash equivalents, beginning of year |
| 194,952 |
| 61,992 | ||
Cash and cash equivalents, end of year | $ | 45,095 | $ | 271,412 | ||
Noncash activities: |
|
|
|
| ||
Accounts receivable recorded in intercompany account | $ | — | $ | (1) | ||
Change in fair value of available-for-sale securities, net of tax | $ | (803) | $ | — | ||
Deferred financing fees charged to stock issuance costs | $ | — | $ | 12 | ||
Net equity effect of preferred share exchange | $ | — | $ | (11,961) | ||
Transfer of construction in progress into property and equipment and intangibles | $ | 2,419 | $ | — | ||
Transfer of inventory into property and equipment | $ | 4,291 | $ | 452 | ||
Supplemental cash flow information: |
|
|
|
| ||
Interest received | $ | 406 | $ | 229 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
1. Nature of operations
The Company is a veterinary health company creating point-of-care diagnostics and therapeutics products for dogs and cats that focuses on the needs of the veterinarians themselves. The Company consists of the parent company, Zomedica Corp and its wholly-owned U.S subsidiary, Zomedica Inc. and its international subsidiaries.
The impact of the novel strain of coronavirus (“COVID-19”)
Since the first quarter of 2020, the world has been impacted by the spread of a novel strain of coronavirus, its variants, and the disease that they cause known as COVID-19. The continued presence of COVID-19 has resulted in changes in the macro-economic environment including disruptions in supply chain, labor disruptions, an inability to manufacture, an inability to sell to customers, declines in customer demand, inflationary pressures, and an impaired ability to access credit and capital markets, among other things.
The COVID-19 pandemic materially and adversely affected the development and commercialization of our TRUFORMA® platform and the initial five assays. In response to the pandemic, our development partner reduced the number of employees working in its facilities for a period of time which delayed the completion and verification of the five initial TRUFORMA assays and the manufacturing of commercial quantities of the TRUFORMA platform. Veterinary hospitals and clinics that agreed to participate in the validation of our initial TRUFORMA assays either shut down for a period of time or limited their operations to those involving only life-threatening conditions, which we have mitigated to a certain extent with our recent ability to successfully complete remote installations. Potential customers, at times, restricted access to their facilities which affected and may continue to affect our ability to perform on-site demonstrations and other marketing activities.
The extent to which the COVID-19 pandemic may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the spread and severity of COVID-19, and the effectiveness of governmental actions in response to the pandemic.
To-date, the emergence of new variants has not caused significant modification to business operations. We continue to install remotely, if potential customers restrict access to their facilities. We intend to continue development of new assays, both for equine indications of our current and planned assays, and for various additional disease states affecting canine, feline, and equine patients in the future.
2. Basis of preparation
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for the presentation of interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited financial statements do not include all the information and footnotes necessary for a comprehensive presentation of the financial position, results of operations and cash flows for the periods presented. In the opinion of management, the unaudited financial statements include all the normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022. These unaudited financial statements should be read in combination with the other Notes in this section; “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing in Item 2; and the Consolidated Financial Statements, including the Notes to the Consolidated Financial Statements, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The Consolidated Balance Sheet as of December 31, 2021 was derived from audited financial statements.
3. Significant accounting policies
Change in accounting for TRUFORMA instruments
As of September 30, 2022, the company changed its policy of recognizing TRUFORMA instruments as inventory and reclassified $3,364 to property and equipment, depreciable over 10 years. The instruments will remain undepreciated until they are placed with customers.
7
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
Estimates and assumptions
In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Investment Securities
Our investment securities, which are comprised of corporate bonds/notes and US treasuries, are accounted for in accordance with ASC 320, “Investments – Debt and Equity Securities” (“ASC 320”). The company considers all of its securities for which there is a determinable fair market value, and there are no restrictions on the Company’s ability to sell within the next 12 months, as available for sale. We classify these securities as both current and non-current depending on their time to maturity. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported as a component of stockholders’ equity
Inventories
Inventories are stated at the lower of cost or net realizable value. The Company utilizes the specific identification and First in, First out (“FIFO”) methods to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions, and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
Intangible assets
Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to website application and infrastructure development are capitalized and amortized over the website’s estimated useful life.
Costs related to acquired trademarks, tradenames, customer relationships and developed technology have been capitalized and amortized over the estimated useful life.
Revenue recognition and liabilities due to customers
The Company enters into agreements which may contain multiple promises where customers purchase products, services, or a combination thereof. Determining whether products and services are considered distinct performance obligations that should be accounted for separately requires judgment. We determine the transaction price for a contract based on the total consideration we expect to receive in exchange for the transferred goods or services.
The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately.
The Company's contracts with customers are generally comprised of purchase orders for the sale of the point of care instrument, consumable products, and extended warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The extended warranties are also a separate performance obligation, whereby revenue is recognized over time.
8
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
The nature of the Company’s business gives rise to variable consideration, including discounts and applicator (“trode”) returns. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. Discounts and the estimated unused shock credits decrease the transaction price, which reduces revenue. Variable consideration related to unused shock credits is estimated using the expected value method, which estimates the amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Estimates of variable consideration are based upon historical experience and known trends. These estimated credits are nonrefundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, so the customer will always have a trode on hand with ample capacity to perform treatments.
At times the Company receives consideration prior to when the performance obligation is completed, giving rise to a contract liability. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority.
Segmented revenue for the three and nine months ended, September 30, 2022 was as follows:
Accounts receivable are recorded at net realizable value and have payment terms of 30 days. The Company recorded an allowance for doubtful accounts of $36 and $34, as of September 30, 2022 and December 31, 2021, respectively, which is recorded net in trade receivables.
Cost of revenue
Cost of revenue consists of materials, labor, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of revenue.
Comparative figures
Construction in progress is separately stated in the current period balance sheet for $202. The consolidated balance sheets for the year ended December 31, 2021 have been adjusted for $420 of construction in progress that was included in intangible assets and property and equipment. This amount has been reclassified to a separate line in the balance sheet to conform to the current year presentation. The change in presentation had no effect on the reported results of operations. These changes in classification do not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.
4. Investment securities
The following represents the Company’s investment securities as of September 30, 2022 (in thousands):
9
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
Accretion / (amortization) refers to the discounts and premiums incurred on bonds and notes purchased and are included within interest income on our consolidated income statement.
Accrued interest receivables related to the above investment securities amounted to $405 and are included within Other Receivables on our consolidated balance sheet.
Contractual maturities of investment securities as of September 30, 2022 are as follows (in thousands):
5. Fair value measurements
In accordance with FASB ASC 820, “Fair Value Measurements and Disclosures,” (“ASC 820”), the Company measures its cash and cash equivalents and investments at fair value on a recurring basis. The company also measures certain assets and liabilities at fair value on a non-recurring basis when applying acquisition accounting.
ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.
As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1: | Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities. |
Level 2: | Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. |
Level 3: | Unobservable data points for the assets or liability, and include situations where there is little, if any, market activity for the asset or liability. Valuations based on inputs that are unobservable and involve management judgement and the reporting entity’s own assumptions about market participants and pricing. |
Cash and cash equivalents, accounts receivable, and accounts payable: The carrying amount of these assets approximate fair value due to the short maturity of these instruments. Cash and cash equivalents include marketable securities that are maturing within 90 days.
Available-for-sale securities: The Company classifies marketable securities and other highly liquid investments, with a maturity of greater than three months and that can be readily purchased or sold using established markets, as available-for-sale. These investments are reported at fair value on the Company’s consolidated balance sheets and unrealized gains and losses are reported as a component of stockholders’ equity.
Included within these available-for-sale securities is our $1M convertible note associated with Structured Monitoring Products, Inc.’s (“SMP”) VetGuardian line. There were no unrealized gains or losses recorded and no other than temporary impairments recognized as of September 30, 2022.
10
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
In accordance with the fair value hierarchy described above, the following table shows the fair value of our investments as of September 30, 2022:
Level 1 | Level 2 | Level 3 | Estimated | |||||||||
Commercial paper | $ | $ | 51,219 | $ | - | $ | 51,219 | |||||
Corporate notes / bonds | 38,703 | - | 38,703 | |||||||||
Debt security | - | - | 1,000 | 1,000 | ||||||||
Money market funds | 2,020 | - | - | 2,020 | ||||||||
U.S. govt. agencies | 33,944 | - | - | 33,944 | ||||||||
U.S. treasuries | 24,697 | - | 24,697 | |||||||||
Total investment securities | $ | 60,661 | $ | 89,922 | $ | 1,000 | $ | 151,583 |
The following table shows these same investments and their respective balance sheet classifications:
Unrealized losses on our investments have not been recorded into income as we do not intend to sell nor is it more likely than not that we will be required to sell these investments prior to recovery of their amortized cost basis. The decline in fair value of our debt securities is largely due to the rising interest rate environment driven by current market conditions that have resulted in higher credit spreads. The credit ratings associated with our debt securities are mostly unchanged, are highly rated, and the debtors continue to make timely principal and interest payments. As a result, there were no credit or non-credit impairment charges recorded through September 30, 2022.
6. Business combinations
All of the Company’s acquisitions of business have been accounted for under ASC 805, Business Combinations. Accordingly, the assets of the acquired companies reflect the fair values and have been included in the Company’s Condensed Financial Statements from their respective dates of acquisition.
The results of operations of Pulse Veterinary Technologies, LLC, Revo Squared LLC, and Assisi Animal Health, LLC have been included in the Company’s Condensed Financial Statements since the dates of acquisition on October 1, 2021, June 14, 2022, and July 15, 2022, respectively.
2022 Acquisitions
Asset Purchase Agreement with Assisi Animal Health LLC
On July 15, 2022 (the “Effective Date”), Zomedica Corp. (the “Company”) and its wholly-owned subsidiary Zomedica Inc. entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Assisi Animal Health LLC (“Assisi”), its wholly-owned subsidiary, AAH Holdings LLC (“AAH Holdings,” and together with Assisi as the “Sellers”), and certain of Assisi’s members (the Sellers and such Assisi members are collectively referred to herein as the “Selling Parties”) pursuant to which Zomedica Inc. agreed to acquire substantially all of the assets of the Sellers (the “Acquisition”). The Sellers are in the business of developing, manufacturing, marketing, distributing and selling animal health products which use targeted Pulsed Electromagnetic Field (PEMF) therapy to decrease pain and inflammation, accelerate healing, and reduce anxiety that include the Assisi Loop®, Assisi Loop Lounge®, Assisi DentaLoop® and Calmer Canine® product lines. The Acquisition was consummated on the Effective Date (the “Closing Date”)
11
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
At the closing, Zomedica Inc. paid Assisi a purchase price of $18,293 in cash, which was subject to adjustments based on, among other things, the value of Assisi’s inventory and prepaid expenses at the closing of the Acquisition. $1,400 of the purchase price was deposited into a third-party escrow account to support the Selling Parties’ indemnification obligation under the Purchase Agreement, of which $500 and $900 will be distributed to Assisi on the and anniversary of the Closing Date, respectively, less the amount of prior or pending indemnification claims. An additional $200 of the purchase price was deposited into the escrow account for a period of approximately to support payment of post-closing adjustments to the purchase price, if any. The Company also issued to Assisi a warrant to purchase an aggregate of 22,000,000 of the Company’s common shares at a per share exercise price equal to $0.252. The warrants may be exercised on a cash or cashless basis, at the election of the warrant holder.
As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $14,329 was recorded in connection with this acquisition, none of which will be deductible for US tax purposes. The goodwill largely results from our ability to market and sell their respective products and services through our established customer base.
The Company made a preliminary allocation of the purchase price for Assisi Animal Health LLC’s asset base based on its understanding of the fair value of the acquired assets and assumed liabilities. As the Company continues to obtain additional information about these assets and liabilities, including intangible asset appraisals, inventory valuation, and accrued expenses, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the acquisition period.
The following table summarizes the preliminary acquisition date fair values of the assets acquired and liabilities assumed and subsequent initial period adjustments:
Purchase price consideration was made up of the following:
Cash | $ | 18,293 | |
Fair value of warrants | $ | 4,688 | |
Total | $ | 22,981 |
The determination of the final purchase price allocation to specific assets and liabilities assumed is incomplete. The purchase price allocation may change in future periods as the fair value estimates of the assets (including intangibles) and liabilities are adjusted.
12
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
The following table provides unaudited proforma financial information, prepared in accordance with Topic 805, for the 3 and 9 months ended September 30, 2022, and 2021, as if Assisi had been acquired as of January 1, 2021. Proforma results do not include the effect of any synergies anticipated to be achieved from the acquisition, and accordingly, are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the date indicated or that may result in the future.
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||
2022 |
| 2021 |
| 2022 |
| 2021 | |||||
Net Revenue | $ | 5,086 | $ | 1,330 | $ | 15,681 | $ | 3,652 | |||
Net Losses | $ | (4,995) | $ | (6,512) | $ | (14,845) | $ | (15,286) |
The proforma amounts have been calculated by including the results of Assisi, and adjusting the combined results to give effect to the following, as if the acquisitions had been consummated on January 1, 2021, together with the consequential tax effects thereon:
Asset Purchase Agreement with Revo Squared LLC
On June 14, 2022, Zomedica Corp. (“Company”) and its wholly-owned subsidiary Zomedica Inc. entered into an Asset Purchase Agreement (“Purchase Agreement”) with Revo Squared LLC (“Revo Squared”) and its majority member (Revo Squared and its majority member are referred to herein as the “Selling Parties”) pursuant to which Zomedica Inc. agreed to acquire substantially all of the assets of Revo Squared (“Acquisition”). Revo Squared, based in Marietta, Georgia, is in the business of developing, manufacturing, marketing, distributing, and selling diagnostic imaging products and services for use in animal health, including its SuperView, Sonoview Color, Sonoview Mini/Mini Plus and Microview product offerings (the “Revo Squared Products”).
On July 1, 2022, the parties consummated the Acquisition. At the closing, Zomedica Inc. paid Revo Squared a base purchase price of $6,011 in cash, which was subject to adjustments based on the amount of Revo Squared’s working capital at the closing. On this date, $500 of the purchase price was deposited into a third-party escrow account for a period of to support Revo Squared’s indemnification obligation under the Purchase Agreement and an additional $50 of the purchase price was deposited into the escrow account for a period of approximately to support payment of post-closing adjustments to the purchase price, if any. The Company also issued to Revo Squared a warrant to purchase an aggregate of 10,000,000 of the Company’s common shares at a per share exercise price equal to $0.2201. Zomedica Inc. has agreed to pay Revo Squared aggregate earn-out payments of up to $4,000 based on the achievement of milestones related to future net sales from Revo Squared Products. -time earn-out payments of $2,000 each will be payable upon net sales from Revo Squared Products exceeding $5,000 and $10,000 during any calendar year ending on or prior to December 31, 2027.
As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $6,528 was recorded in connection with this acquisition, which will be deductible for US tax purposes. The goodwill largely results from our ability to market and sell their respective products and services through our established customer base.
The Company made a preliminary allocation of the purchase price for Revo Squared’s asset base based on its understanding of the fair value of the acquired assets and assumed liabilities. As the Company continues to obtain additional information about these assets and liabilities, including intangible asset appraisals, inventory valuation, and accrued expenses, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the acquisition period.
13
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
The following table summarizes the preliminary acquisition date fair values of the assets acquired and liabilities assumed and subsequent initial period adjustments:
| Initial | ||
Allocation of | |||
| Consideration | ||
Trade receivables, net | $ | 8 | |
Prepaid expenses and deposits |
| 10 | |
Intangible Assets (estimated useful life) |
| ||
Customer relationships (16 years) |
| 1,200 | |
Developed technology (10 years) |
| 2,300 | |
Trade name (5 years) |
| 200 | |
Total assets acquired |
| 3,718 | |
Earnout liabilities |
| 2,458 | |
Total liabilities assumed |
| 2,458 | |
Net assets acquired, excluding goodwill |
| 1,260 | |
Goodwill |
| 6,528 | |
Net assets acquired | $ | 7,788 |
Purchase price consideration was made up of the following:
Cash | $ | 6,011 | |
Fair value of warrants | $ | 1,777 | |
Total | $ | 7,788 |
The determination of the final purchase price allocation to specific assets and liabilities assumed is incomplete. The purchase price allocation may change in future periods as the fair value estimates of the assets (including intangibles) and liabilities are adjusted.
2021 Acquisitions
Acquisition of PulseVet®
On October 1, 2021, Zomedica Inc., a wholly-owned subsidiary of Zomedica Corp. (the “Company”), entered into a Stock Purchase Agreement with Branford PVT Mid-Hold, LLC pursuant to which Zomedica Inc. acquired 100% of the capital stock of Branford PVT Acquiror, Inc., a Delaware corporation (“BPA”). BPA is a holding company whose direct and indirect wholly-owned subsidiaries include Pulse Veterinary Technologies, LLC (“PulseVet”), which, together with its consolidated subsidiaries, is a leading provider of non-invasive shock wave therapy treatment devices to the veterinary industry (the “Acquisition”). The purchase price for the acquisition was $71,929 in cash.
As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $44,915 was recorded in connection with this acquisition, none of which will be deductible for U.S tax purposes. The goodwill largely results from our ability to market and sell the PulseVet Technology through our established customer base.
The Company finalized the allocation of the purchase price for PulseVet as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities.
14
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows
| Initial |
| Measurement |
| |||||
Allocation of | Period | Updated | |||||||
| Consideration |
| Adjustments |
| Allocation | ||||
Cash and cash equivalents | $ | 526 | $ | 3 | $ | 529 | |||
Trade receivables |
| 269 |
| — |
| 269 | |||
Inventory |
| 840 |
| 31 |
| 871 | |||
Prepaid expenses and deposits |
| 365 |
| — |
| 365 | |||
Other receivables |
| — |
| 150 |
| 150 | |||
Property and equipment |
| 125 |
| — |
| 125 | |||
Intangible Assets (estimated useful life) |
| ||||||||
Customer relationships (11 years) |
| 22,650 |
| — |
| 22,650 | |||
Developed technology (15 years) |
| 8,650 |
| — |
| 8,650 | |||
Trade name (19 years) |
| 2,350 |
| — |
| 2,350 | |||
Other Assets |
| 69 |
| 265 |
| 334 | |||
Total assets acquired |
| 35,844 |
| 449 |
| 36,293 | |||
Accounts payable and accrued liabilities |
| 1,112 |
| (543) |
| 569 | |||
Income tax payable |
| 44 |
| — |
| 44 | |||
Deferred revenue |
| 61 |
| — |
| 61 | |||
Liability for contracts with customers |
| 332 |
| — |
| 332 | |||
Deferred tax liabilities |
| 7,138 |
| (814) |
| 6,324 | |||
Other non current liabilities |
| 143 |
| 265 |
| 408 | |||
Total liabilities assumed |
| 8,830 |
| (1,092) |
| 7,738 | |||
Net assets acquired, excluding goodwill |
| 27,014 |
| 1,541 |
| 28,555 | |||
Goodwill |
| 44,915 |
| (1,541) |
| 43,374 | |||
Net assets acquired | $ | 71,929 | $ | — | $ | 71,929 |
7. Inventory
Inventory details are as follows:
September 30, 2022 | December 31, 2021 | |||||||||||||||||
Diagnostics |
| Therapeutics |
| Consolidated |
| Diagnostics |
| Therapeutics |
| Consolidated | ||||||||
Raw Materials | $ | — | $ | 1,700 | $ | 1,700 | $ | — | $ | 890 | $ | 890 | ||||||
Finished Goods |
| — |
| 175 |
| 175 |
| — |
| 140 |
| 140 | ||||||
Purchased Inventory |
| 554 |
| — |
| 554 |
| 1,848 |
| — |
| 1,848 | ||||||
Total |
| 554 |
| 1,875 |
| 2,429 |
| 1,848 |
| 1,030 |
| 2,878 | ||||||
|
| |||||||||||||||||
Reserves |
| (7) |
| (22) |
| (29) |
| (9) |
| (21) |
| (30) | ||||||
Inventory, Net | $ | 547 | $ | 1,853 | $ | 2,400 | $ | 1,839 | $ | 1,009 | $ | 2,848 |
15
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
8. Prepaid expenses and deposits
| September 30, |
| December 31, | |||
2022 | 2021 | |||||
Deposits | $ | 2,114 | $ | 1,340 | ||
Prepaid marketing |
| 125 |
| 83 | ||
Prepaid insurance |
| 185 |
| 599 | ||
Prepaid taxes |
| 822 |
| — | ||
Other |
| 595 |
| 214 | ||
Total | $ | 3,841 | $ | 2,236 |
9. Property and equipment
| September 30, |
| December 31, | |||
2022 | 2021 | |||||
Machinery and office equipment | $ | 6,248 | $ | 1,392 | ||
Furniture and equipment |
| 130 |
| 110 | ||
Laboratory equipment |
| 231 |
| 225 | ||
Leasehold improvements |
| 1,239 |
| 287 | ||
| 7,848 |
| 2,014 | |||
Accumulated depreciation and amortization |
| 1,121 |
| 884 | ||
Net property and equipment | $ | 6,727 | $ | 1,130 |
Depreciation expense for the three months ended September 30, 2022 and September 30, 2021 was $109 and $60, respectively and for the nine months ended September 30, 2022 and September 30, 2021 was $270 and $175, respectively.
10. Intangible assets
| September 30, |
| December 31, | |||
2022 | 2021 | |||||
Computer software | $ | 254 | $ | 28 | ||
Customer relationships |
| 26,650 |
| 22,650 | ||
Technology |
| 15,650 |
| 8,650 | ||
Trademarks |
| 16 |
| 16 | ||
Tradename |
| 2,850 |
| 2,350 | ||
Website |
| 962 |
| 546 | ||
| 46,382 |
| 34,240 | |||
Accumulated amortization |
| 3,604 |
| 1,064 | ||
Net intangibles | $ | 42,778 | $ | 33,176 |
The estimated future amortization of intangible assets is as follows:
2022 Remainder |
| $ | 1,053 |
2023 |
| 4,077 | |
2024 |
| 4,038 | |
2025 |
| 3,873 | |
2026 and beyond |
| 29,737 | |
Total | $ | 42,778 |
16
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
Amortization expense for the three months ended September 30, 2022 and September 30, 2021 was $1,045 and $47, respectively and for the nine months ended September 30, 2022 and 2021 was $2,540 and $136, respectively.
11. Leases
On February 1, 2021 the Company downsized its office space and modified its existing lease with Wickfield Phoenix LLC. The new lease period was for 48 months, commencing on February 1, 2021 and ending on January 31, 2025 with a monthly rent payment of $12 for the first two months and escalating to $31 over the lease period. The carrying value of the right of use asset was $1,258 upon modification using the Company's incremental borrowing rate of 3.95%. During the period ending March 31, 2021 the Company recorded a gain on right-of-use asset of $24 in the consolidated statements of comprehensive loss.
On September 15, 2021, the Company entered into an additional lease with Wickfield Phoenix LLC for warehousing space. The new lease period is for 41 months, commencing on September 15, 2021, and ending on January 31, 2025, with a monthly rent payment of $5 for the first month and escalating to $10 over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $366 using the Company's incremental borrowing rate of 3.95%.
On April 1, 2022, the Company entered into an agreement with ULF Northfield Business Center LLC to lease 12,400 square feet of office and warehouse space. The lease period is for 61 months beginning on April 1, 2022, with a monthly rent payment of $9 for the first twelve months and escalating to $11 per month over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $546 using the Company's incremental borrowing rate of 3.95%.
On July 1, 2022, the Company, as part of the Revo Squared Purchase, assumed an agreement with Lebow 1031 Legacy, LLC to lease 4,626 square feet of office space. The remaining lease period assumed at the time of the agreement is for 18 months beginning on July 1, 2022 and lasting through December of 2023. The lease has a monthly rent payment of $4 per month over the lease period. The Company recorded a right-of-use asset and corresponding lease liability for $67 using the Company's incremental borrowing rate of 7.00%.
During the three and nine months ended September 30, 2022, the Company recognized $268 and $598 in rent expense inclusive of common area maintenance (CAM) charges, insurance, and tax with $15 and $48 recorded in research and development expenses and $253 and $550 recorded in general and administrative expense in the consolidated statements of comprehensive loss.
During the three and nine months ended September 30, 2021, the Company recognized $94 and $271 in rent expense inclusive of common area maintenance (CAM) charges, insurance, and tax with $32 and $69 recorded in research and development expenses and $62 and $202 recorded in general and administrative expense in the consolidated statements of comprehensive loss.
17
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
September 30, | December 31, | |||||
| 2022 | 2021 | ||||
Right-of-use asset |
|
|
|
|
| |
Cost |
|
|
|
| ||
Aggregate lease commitments | $ | 2,455 | $ | 1,779 | ||
Less: impact of present value |
| (218) | (155) | |||
Balance | $ | 2,237 | $ | 1,624 | ||
Reduction in right-of-use asset |
|
|
| |||
Straight line amortization |
| 761 | 346 | |||
Interest |
| (91) | (42) | |||
Balance | $ | 670 | $ | 304 | ||
Net book value as at: | ||||||
Balance | $ | 1,567 | $ | 1,320 | ||
Lease liabilities | ||||||
Additions | $ | 2,260 | $ | 1,647 | ||
Payments |
| (715) | (310) | |||
Interest |
| 91 | 42 | |||
Total lease liabilities | $ | 1,636 | $ | 1,379 | ||
Current portion of lease liabilities |
| 578 | 415 | |||
Long term portion of lease liabilities |
| 1,058 | 964 | |||
Total lease liabilities | $ | 1,636 | $ | 1,379 |
Total remaining undiscounted lease liabilities related to the above lease are as follows:
| |||
2022 Remainder |
| $ | 155 |
2023 | 638 | ||
2024 |
| 609 | |
2025 |
| 165 | |
2026 | 129 | ||
2027 | 44 | ||
Total | $ | 1,740 |
12. Stock-based compensation
During the three and nine months ended September 30, 2022, the Company issued 7,075,000 and 28,075,000 stock options to purchase an aggregate of 7,075,000 and 28,075,000 common shares. The options vest over a period of four years and have an expiration period of ten years. During the three and nine months ended September 30, 2021, the Company issued 2,900,000 and 12,100,000 stock options to purchase an aggregate of 2,900,000 and 12,100,000 common shares, respectively. The options vest over a period of four years and have an expiration period of 10 years.
The continuity of stock options are as follows:
18
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
As of September 30, 2022, details of the issued and outstanding stock options were as follows:
|
|
|
| Number of |
| Weighted Avg | ||||
Number of Options | Number of | Unvested | Remaining Life | |||||||
Issued | Vested Options | Options | Outstanding | |||||||
Grant Date |
| Exercise Price |
| and Outstanding |
| Outstanding |
| Outstanding |
| (Years) |
March 14, 2020 |
| 0.19 |
| 75,000 |
| 75,000 |
| — |
| 0.01 |
March 14, 2020 |
| 0.19 |
| 37,500 |
| 37,500 |
| — |
| 0.21 |
March 14, 2020 |
| 0.19 |
| 1,133,557 |
| 837,182 |
| 296,375 |
| 2.45 |
July 9, 2020 |
| 0.18 |
| 175,000 |
| 131,250 |
| 43,750 |
| 2.78 |
August 25, 2020 |
| 0.13 |
| 20,000 |
| 10,000 |
| 10,000 |
| 2.90 |
October 1, 2020 |
| 0.11 |
| 266,667 |
| 116,667 |
| 150,000 |
| 3.01 |
October 20, 2020 |
| 0.09 |
| 20,000 |
| 10,000 |
| 10,000 |
| 3.06 |
December 31, 2020 |
| 0.23 |
| 125,000 |
| 125,000 |
| — |
| 0.01 |
December 31, 2020 |
| 0.23 |
| 50,000 |
| 50,000 |
| — |
| 0.21 |
December 31, 2020 |
| 0.23 |
| 15,742,500 |
| 8,632,500 |
| 7,110,000 |
| 8.25 |
February 26, 2021 |
| 1.87 |
| 100,000 |
| 100,000 |
| — |
| 0.22 |
February 26, 2021 |
| 1.87 |
| 200,000 |
| 100,000 |
| 100,000 |
| 8.41 |
March 1, 2021 |
| 2.06 |
| 200,000 |
| 100,000 |
| 100,000 |
| 8.42 |
March 8, 2021 |
| 1.88 |
| 200,000 |
| 100,000 |
| 100,000 |
| 8.44 |
March 15, 2021 |
| 2.49 |
| 200,000 |
| 100,000 |
| 100,000 |
| 8.46 |
May 12, 2021 |
| 0.78 |
| 3,400,000 |
| 850,000 |
| 2,550,000 |
| 8.62 |
May 14, 2021 |
| 0.75 |
| 3,200,000 |
| 850,000 |
| 2,350,000 |
| 8.62 |
August 11, 2021 | 0.57 |
| 50,000 |
| 50,000 |
| — |
| 0.15 | |
August 11, 2021 | 0.57 |
| 900,000 |
| 225,000 |
| 675,000 |
| 8.87 | |
August 18, 2021 | 0.50 |
| 200,000 |
| 50,000 |
| 150,000 |
| 8.89 | |
August 23, 2021 | 0.50 |
| 100,000 |
| 25,000 |
| 75,000 |
| 8.90 | |
September 13, 2021 | 0.57 |
| 800,000 |
| 200,000 |
| 600,000 |
| 8.96 | |
October 1, 2021 | 0.58 |
| 12,650,000 |
| — |
| 12,650,000 |
| 9.01 | |
January 3, 2022 | 0.36 |
| 100,000 |
| — |
| 100,000 |
| 9.27 | |
January 4, 2022 | 0.35 |
| 200,000 |
| — |
| 200,000 |
| 9.27 | |
January 14, 2022 | 0.35 |
| 200,000 |
| — |
| 200,000 |
| 9.30 | |
January 16, 2022 | 0.35 |
| 200,000 |
| — |
| 200,000 |
| 9.30 | |
January 18, 2022 | 0.35 |
| 100,000 |
| — |
| 100,000 |
| 9.31 | |
February 14, 2022 | 0.30 |
| 200,000 |
| — |
| 200,000 |
| 9.38 | |
February 21, 2022 | 0.37 |
| 200,000 |
| — |
| 200,000 |
| 9.40 | |
February 25, 2022 | 0.35 |
| 12,300,000 |
| — |
| 12,300,000 |
| 9.41 | |
March 30, 2022 | 0.35 |
| 200,000 |
| — |
| 200,000 |
| 9.50 | |
April 1, 2022 | 0.34 |
| 200,000 |
| — |
| 200,000 |
| 9.51 | |
April 6, 2022 | 0.32 |
| 100,000 |
| — |
| 100,000 |
| 9.52 | |
April 11, 2022 | 0.31 |
| 75,000 |
| — |
| 75,000 |
| 9.54 | |
May 2, 2022 | 0.25 |
| 300,000 |
| — |
| 300,000 |
| 9.59 | |
May 9, 2022 | 0.21 |
| 700,000 |
| — |
| 700,000 |
| 9.61 | |
May 11, 2022 | 0.20 |
| 400,000 |
| — |
| 400,000 |
| 9.62 | |
May 16, 2022 | 0.23 |
| 100,000 |
| — |
| 100,000 |
| 9.63 | |
May 31, 2022 | 0.24 |
| 500,000 |
| — |
| 500,000 |
| 9.67 | |
June 1, 2022 | 0.25 |
| 500,000 |
| — |
| 500,000 |
| 9.68 | |
June 6, 2022 | 0.26 |
| 200,000 |
| — |
| 200,000 |
| 9.69 | |
June 13, 2022 | 0.24 |
| 200,000 |
| — |
| 200,000 |
| 9.71 | |
June 17, 2022 | 0.24 |
| 375,000 |
| 375,000 |
| — |
| 2.45 | |
June 17, 2022 | 0.24 |
| 225,000 |
| 225,000 |
| — |
| 3.00 | |
June 17, 2022 | 0.24 |
| 2,500,000 |
| 2,500,000 |
| — |
| 8.26 | |
July 1, 2022 | 0.21 |
| 350,000 |
| — |
| 350,000 |
| 9.76 | |
July 5, 2022 | 0.22 |
| 200,000 |
| — |
| 200,000 |
| 9.77 | |
July 6, 2022 | 0.26 |
| 100,000 |
| — |
| 100,000 |
| 9.77 | |
July 25, 2022 | 0.25 |
| 200,000 |
| — |
| 200,000 |
| 9.82 | |
August 1, 2022 | 0.28 |
| 100,000 |
| — |
| 100,000 |
| 9.84 | |
August 5, 2022 | 0.34 |
| 2,850,000 |
| — |
| 2,850,000 |
| 9.85 | |
August 8, 2022 | 0.39 |
| 100,000 |
| — |
| 100,000 |
| 9.86 | |
August 17, 2022 | 0.31 |
| 200,000 |
| — |
| 200,000 |
| 9.89 | |
August 19, 2022 | 0.27 |
| 400,000 |
| — |
| 400,000 |
| 9.89 |
19
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
August 22, 2022 | 0.27 |
| 400,000 |
| — |
| 400,000 |
| 9.90 | |
August 29, 2022 | 0.27 |
| 400,000 |
| — |
| 400,000 |
| 9.92 | |
August 31, 2022 | 0.25 |
| 800,000 |
| — |
| 800,000 |
| 9.93 | |
September 6, 2022 | 0.21 |
| 75,000 |
| — |
| 75,000 |
| 9.94 | |
September 21, 2022 | 0.23 |
| 200,000 |
| — |
| 200,000 |
| 9.98 | |
September 23, 2022 | 0.21 |
| 400,000 |
| — |
| 400,000 |
| 9.99 | |
September 26, 2022 | 0.22 |
| 300,000 |
| — |
| 300,000 |
| 10.00 | |
Balance at September 30, 2022 |
|
| 66,995,224 |
| 15,875,099 |
| 51,120,125 |
|
|
The Company calculates volatility of stock-based compensation using the historical price of the Company’s stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options.
The fair value of options granted during the nine months ended September 30, 2022 and the twelve months ended December 31, 2021 was estimated using the Black-Scholes option pricing model to determine the fair value of options granted using the following assumptions:
20
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
August 19, 2022 | 113 | 3.09 | 6.25 | 0 | 0.27 | 0.27 | 0 | ||||||||||||||
August 19, 2022 | 113 | 3.09 | 6.25 | 0 | 0.27 | 0.27 | 0 | ||||||||||||||
August 22, 2022 | 113 | 3.15 | 6.25 | 0 | 0.27 | 0.27 | 0 | ||||||||||||||
August 22, 2022 | 113 | 3.15 | 6.25 | 0 | 0.27 | 0.27 | 0 | ||||||||||||||
August 29, 2022 | 113 | 3.24 | 6.25 | 0 | 0.26 | 0.27 | 0 | ||||||||||||||
August 29, 2022 | 113 | 3.24 | 6.25 | 0 | 0.26 | 0.27 | 0 | ||||||||||||||
August 31, 2022 | 113 | 3.28 | 6.25 | 0 | 0.24 | 0.25 | 0 | ||||||||||||||
September 6, 2022 | 113 | 3.42 | 6.25 | 0 | 0.21 | 0.21 | 0 | ||||||||||||||
September 21, 2022 | 113 | 3.70 | 6.25 | 0 | 0.23 | 0.23 | 0 | ||||||||||||||
September 23, 2022 | 113 | 3.91 | 6.25 | 0 | 0.21 | 0.21 | 0 | ||||||||||||||
September 23, 2022 | 113 | 3.91 | 6.25 | 0 | 0.21 | 0.21 | 0 | ||||||||||||||
September 26, 2022 | 113 | 4.11 | 6.25 | 0 | 0.22 | 0.22 | 0 | ||||||||||||||
September 26, 2022 | 113 | 4.11 | 6.25 | 0 | 0.22 | 0.22 | 0 |
The Company recorded $1,920 and $6,452 of stock-based compensation for the three and nine months ended September 30, 2022, respectively. For the three and nine months ended September 30, 2021, the Company recorded $1,438 and $4,503, respectively.
13. Warrants
The Company values warrants issued in equity placements using the Black Scholes model to allocate the fair value of the proceeds from equity financings using a relative fair value approach. Like other stock-based compensation, management uses judgment to determine the inputs to the Black-Scholes option pricing model including the expected life, and underlying share price volatility. Changes in these assumptions will impact the calculation of fair value and the value attributed to the warrants. The Company calculates volatility of warrants based on the historical price of the Company’s stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options.
In connection with the February 14, 2020 registered direct offering, the Company issued 20,833,334 Series A warrants to purchase 20,833,334 shares of common stock at an exercise price of $0.20. The Company also issued 1,041,667 warrants to purchase 1,041,667 shares of common stock at an exercise price of $0.15 per share to the placement agents.
In connection with the April 9, 2020 Confidentiality Marketed Public Offering (CMPO), the Company issued 16,666,667 five-year Series B Warrants to purchase 16,666,667 common shares at an exercise price of $0.15. The Company also issued 1,666,667 Placement Agent Warrants to purchase 1,666,667 common shares at an exercise price of $0.15 per share.
In connection with the May 29, 2020 public offering, the Company issued 133,333,333 two-year Series C Warrants to purchase 133,333,333 common shares at an exercise price of $0.15. The Company also issued 12,170,000 Series C Pre-Funded Warrants to purchase common shares at an exercise price of $0.0001 on a cashless exercise basis. As of December 31, 2020, all of the Series C Pre-Funded warrants had been exercised.
In connection with the July 7, 2020 public offering, the Company issued 187,500,000 two-year Series D Warrants to purchase 187,500,000 common shares at an exercise price of $0.16. The Company also issued 25,000,000 Series D Pre-Funded Warrants to purchase common shares at an exercise price of $0.0001 on a cashless exercise basis. As of December 31, 2020, all of the Series D Pre-Funded Warrants had been exercised.
In connection with the July 1, 2022 asset acquisition of Revo Squared, the Company issued a ten-year warrant to purchase 10,000,000 common shares at a per share exercise price equal to $0.2201. The warrants may be exercised on a cash or cashless basis, at the election of the warrant holder. As of September 30, 2022, no warrants have been exercised.
In connection with the July 15, 2022 asset acquisition of Assisi, the Company issued a ten-year warrant to purchase 22,000,000 common shares at a per share exercise price equal to $0.252. The warrants may be exercised on a cash or cashless basis, at the election of the warrant holder. As of September 30, 2022, no warrants have been exercised.
21
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
As of September 30, 2022, details of the outstanding warrants were as follows:
|
|
| Weighted | |||
Average | ||||||
Exercise | Warrants | Remaining | ||||
Original Issue date | Price | Outstanding | Life | |||
February 14, 2020 | 0.1500 | 197,917 | 2.37 | |||
April 9, 2020 | 0.1500 | 363,501 | 2.53 | |||
July 1, 2022 | 0.2201 | 10,000,000 | 9.76 | |||
July 15, 2022 | 0.2520 | 22,000,000 | 9.80 | |||
Balance at September 30, 2022 |
|
|
| 32,561,418 |
|
|
14. Income taxes
The Company is in an overall net deferred tax liability position as of September 30, 2022. Management has assessed that the future taxable income resulting from the deferred tax liability position will result in utilization of the Company’s US federal and state net operating loss carryforwards in future tax periods. The Company is in a net deferred tax asset position in Canada and a full valuation allowance against the Canada deferred tax assets remains necessary as a result of the historical losses and the uncertainty of realizing any future tax benefits related to the Canadian deferred tax assets.
15. Commitments and contingencies
On May 10, 2018, the Company entered into a Development, Commercialization and Exclusive Distribution Agreement. As part of the agreement, the Company is required to make the following future milestone payments:
● | 1st payment: $3,500 in cash payment upon the achievement of future development milestones |
● | 2nd payment: $3,500 in equity, determined by dividing the amount due by the volume-weighted average price of the Company’s common stock on the NYSE American exchange over the 10 trading days prior to the achievement of the milestone event. |
As of September 30, 2022, none of the future development milestones related to the above agreement have been met. The Company has assessed the probability of meeting the above milestones and has determined that an accrual is not necessary as of September 30, 2022 and December 31, 2021.
From time to time, the Company may be exposed to claims and legal actions in the normal course of business. The Company is not aware of any pending or threatened material litigation claims against the Company.
16. Segment information
The Company’s operations are comprised of two reportable segments:
● | Diagnostics, which consists of TRUFORMA products, and |
● | Therapeutics, which consists of PulseVet and Assisi products |
The Company’s Chief Operating Decision Maker (CODM) is its Chief Executive Officer who has ultimate responsibility for enterprise decisions.
Although our reportable segments provide similar products, each one is managed separately to better align with the Company’s customers and distribution / development partners. The CODM determines resource allocation for, and monitors performance of, the consolidated enterprise, the Diagnostics segment, and the Therapeutics segment together. The CODM relies on internal segment reporting that analyzes results on certain key performance indicators, namely, revenues and gross profit. Costs below gross profit are not allocated to the segments.
22
Zomedica Corp.
Notes to the condensed consolidated financial statements
(Unaudited) (United States dollars in thousands, except for per share data)
The following is a reconciliation of consolidated revenue, cost of revenue, and gross profit amongst our reportable segments:
| Diagnostics |
| Therapeutics |
| Consolidated | ||||
Net revenue | $ | 242 | $ | 12,531 | $ | 12,773 | |||
Cost of revenue |
| 149 |
| 3,266 |
| 3,415 | |||
Gross profit (loss) | $ | 93 | $ | 9,265 | $ | 9,358 |
17. Loss per share
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 | |||||
Numerator |
|
|
|
| ||||||||
Net loss for the period | $ | (4,995) | $ | (6,346) | $ | (14,206) | $ | (15,093) | ||||
Charge to retained earnings for preferred share exchange |
| - |
| - |
| - |
| (32,039) | ||||
Loss attributable to common shareholders | (4,995) | (6,346) | (14,206) | (47,132) | ||||||||
Denominator |
|
| ||||||||||
Weighted average shares - basic |
| 979,946,407 | 978,494,076 | 979,915,419 | 948,664,410 | |||||||
Stock options |
| — |
| — |
| — |
| — | ||||
Warrants |
| — |
| — |
| — |
| — | ||||
Denominator for diluted loss per share |
| 979,946,407 |
| 978,494,076 |
| 979,915,419 |
| 948,664,410 | ||||
Loss per share - basic and diluted | $ | (0.005) | $ | (0.006) | $ | (0.014) | $ | (0.050) |
For the above-mentioned periods, the Company had 66,995,224 stock options and 32,561,418 warrants outstanding which could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti-dilutive.
18. Related party transaction
On March 1, 2022 we entered into a Consulting Agreement with Johnny Powers, a member of our Board. Pursuant to the Powers Agreement, Dr. Powers provides strategic consulting services to the Company. Dr. Powers is entitled to $10 per month as compensation and reimbursement for authorized expenses. The Powers Agreement expires November 30, 2022.
23
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATION
The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes and the other financial information included elsewhere in this Report. This discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Report, and those set forth in our most recent Annual Report on Form 10-K particularly those under “Risk Factors” discussed below and in our most recent Annual Report on Form 10-K.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Report contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and pursuant to applicable Canadian securities legislation that are based on management’s beliefs and assumptions and on information currently available to management. Some of the statements under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Report contain forward-looking statements. In some cases, you can identify forward-looking statements through our use of words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:
● | our ability to successfully maintain and grow our TRUFORMA and PulseVet platforms and our Assisi products; |
● | our ability to maintain our sales team to market and sell TRUFORMA, PulseVet, and Assisi or any other products we develop or acquire and the related cost and timing thereof; |
● | our ability to successfully integrate our recent acquisitions of Assisi and Revo and the timing and costs to achieve that integration; |
● | the ability of our contract partners and contractors to appropriately conduct our product development, validation studies, verification studies, and beta testing, and certain other development activities; |
● | the ability of our contract manufacturing organizations to manufacture and supply our products; |
● | our ability to develop and commercialize our future products; |
● | the expected impact of the novel coronavirus pandemic on our operations; |
● | our ability to develop and commercialize products that can compete effectively; |
● | the size and growth of the veterinary diagnostics and medical device markets; |
● | our ability to obtain and maintain intellectual property protection for our planned and future products candidates; |
● | regulatory developments in the United States; |
● | the loss of key personnel; |
24
● | the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; |
● | the impact of the novel coronavirus pandemic on our operations, including the development, manufacturing and selling of our TRUFORMA platform and related assays, our PulseVet platform, and our Assisi products; |
● | our ability to maintain the listing of our common shares on the NYSE American exchange |
● | our status as a “passive foreign investment company” for U.S. federal income tax purposes |
● | Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy, tighter credit, higher interest rates, high unemployment and currency fluctuations; and |
● | Changes in consumer confidence and spending in response to financial market volatility, negative financial news, conditions in the real estate and mortgage markets, declines in income or asset values, changes to fuel and other energy costs, labor and healthcare costs, and other economic factors. |
The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see “Risk Factors” in our most recent Annual Report on Form 10-K for additional risks which could adversely impact our business and financial performance.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Report or the date of the document incorporated by reference into this Report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. We have expressed our expectations, beliefs and projections in good faith, and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.
All amounts are in thousands of dollars, except earnings per share, unless otherwise stated.
Overview
We are a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Our mission is to enrich the lives of the animals we love and the people that care for them by providing products and technologies that improve patient care and enhance practice health. Our product portfolio includes innovative diagnostics and therapeutic medical devices that emphasize patient health and enhancing practice economics.
We currently have two discrete platforms - our TRUFORMA platform, comprising point-of-care diagnostic products for disease states in dogs and cats, and our PulseVet platform, which provides for treatment of musculoskeletal issues in horses and small animals. In addition, we have a series of Assisi products that use targeted Pulsed Electromagnetic Field (PEMF) therapy to decrease pain and inflammation, accelerate healing, and reduce anxiety.
Dogs and cats commonly suffer from adrenal disorders and thyroid disease, including hypothyroidism and hyperthyroidism. We believe that diagnostic tests are vital for identifying these disorders in sick patients as well as for screening apparently healthy patients. In certain cases, multiple assays must be performed to reach a definitive diagnosis of a specific disease or condition. Clinical veterinarians often do not have access to the equipment and assays to perform this testing at the point-of- care. As a result, certain tests must be sent to a reference lab, resulting in delay in diagnosis and treatment, and depriving clinical veterinarians of potential testing revenue.
Through our TRUFORMA platform, we are focused on the development and commercialization of diagnostic instruments and related assays for use at the point-of-care that provide reference lab accuracy, thereby enabling practitioners to diagnose and treat diseases sooner.
Through our PulseVet platform, we are the world leader in electro-hydraulic shockwave technology for the treatment of a wide variety of conditions in horses and small animals. Our technology is indicated for conditions including osteoarthritis, tendon and ligament healing, bone healing, chronic pain relief and wound healing.
25
As a result of an internal strategic view, we have focused our development and commercialization efforts on our TRUFORMA and PulseVet platforms and our Assisi products. We believe this narrowed focus will enable us to capitalize on our core strengths and to accelerate the commercialization of these existing platforms.
Revenue
Our revenue consisted of instruments, cartridges, extended warranty services and miscellaneous activities sold in the U.S associated with our TRUFORMA platform, instruments, trodes and warranty services sold in the U.S and internationally associated with our PulseVet platform, and consumables sold in the U.S. and internationally associated with our Assisi products.
Cost of Revenue
Cost of revenue consisted primarily of the cost of raw materials used in the assembly of PulseVet instruments and trodes, the cost of TRUFORMA instruments purchased, the cost of Assisi parts purchased and related sub-components, and consumables and the related warranties purchased. We expense all inventory obsolescence provisions related to normal manufacturing changes as cost of revenue.
Operating Expenses
The majority of our operating expenses have been for the selling, general and administrative activities related to general business activities, capital market activities, stock-based compensation, developing a commercial team and research and development activities related to our product development.
Research and Development Expense
All costs of research and development are expensed in the period in which they are incurred. Research and development costs primarily consist of salaries and related expenses for personnel, fees paid to consultants, outside service providers, professional services, travel costs and materials used in clinical trials and research and development.
Selling, General and Administrative Expense
Selling, general and administrative expense consists primarily of personnel costs, including salaries, related benefits and stock-based compensation for employees, consultants and directors. These expenses also include costs associated with sales and marketing activity, professional fees, and corporate administrative and overhead costs, including rent and other facilities costs, amortization, and depreciation.
Income Taxes
As of December 31, 2021, we had net operating loss carryforwards for U.S. federal and state income tax purposes of $28,178 and non-capital loss carryforwards for Canada of approximately $37,280, which will begin to expire in fiscal year 2035. We have evaluated the factors bearing upon the realizability of our deferred tax assets, which are comprised principally of net operating loss carryforwards and non-capital loss carryforwards. We concluded that, due to the limitations under Section 382, our U.S. federal and state net operating loss carryforwards for the periods prior to February 11, 2021 have been limited to zero. We therefore have derecognized $20,976 of our U.S deferred tax assets, resulting in a remaining carryforward balance of $7,202.
In Canada, due to the uncertainty of realizing any tax benefits as of December 31, 2021, and September 30, 2022 we continue to fully value our Canadian deferred tax assets.
Translation of Foreign Currencies
The functional currency, as determined by management, for our subsidiaries in the United States, Switzerland, and Canada is the U.S. dollar, which is also our reporting currency
The functional currency, as determined by management, for our Japanese subsidiary is the Japanese Yen. Japanese Yen are translated for financial reporting purposes with translation gains and losses recorded as a component of other comprehensive income or loss.
26
Stock-Based Compensation
We measure the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted.
We calculate stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of our stock-based compensation plans do not require us to settle any options by transferring cash or other assets, and therefore we classify the awards as equity. Stock-based compensation expense recognized during the period is based on the value of stock-based payment awards that are ultimately expected to vest. We estimate forfeitures at the time of grant and revise these estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based on an average of the term of the options. The risk-free rate assumed in valuing the options is based on the Canadian treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is zero as we are not expected to pay dividends in the foreseeable future.
Loss Per Share
Basic loss per share, or EPS, is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.
Comprehensive Loss
We follow ASC topic 220. This statement establishes standards for reporting and display of comprehensive (loss) income and its components. Comprehensive loss is net loss plus certain items that are recorded directly to shareholders’ equity.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and revenue, costs and expenses and related disclosures during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
While our significant accounting policies are more fully described in Note 3 of the notes to our consolidated financial statements appearing elsewhere in this document, management has identified the following as “Critical Accounting Policies and Estimates”: Intangible Assets and Business Combinations, Inventory Reserves, and Revenue Recognition and Liabilities due to Customers. We believe that the estimates and assumptions involved in these accounting policies may have the greatest potential impact on our financial statements.
Intangible Assets and Business Combinations
Assets acquired and liabilities assumed as part of a business combination are recognized at their acquisition date fair values. In determining these fair values, we utilized various forms of the income, cost and market approaches depending on the asset or liability being valued.
We used a discounted cash flow model to measure the trade names, customer relationship, and technology assets. The estimation of fair value required significant judgment related to future net cash flows based on assumptions related to revenue and EBITDA growth rates, discount rates, and attrition factors. Inputs were generally determined by taking into account competitive trends, market comparisons, independent appraisals, and historical data, among other factors, and were supplemented by current and anticipated market conditions.
27
Variances in future cash flows, anticipated growth rates and revenue could significantly impact the value assigned to intangible assets. Any variance could cause impairment charges upon testing.
We will evaluate goodwill for impairment annually or more frequently when an event occurs or circumstances change indicating the carrying value may not be recoverable. When testing goodwill for impairment, we may first assess qualitative factors to determine if it is more likely than not the carrying value of a reporting unit exceeds its estimated fair value. During a qualitative analysis, we consider the impact of changes, if any, to the following factors: macroeconomic, industry and market factors; cost factors; changes in overall financial performance; and any other relevant events and uncertainties impacting a reporting unit. If our qualitative assessment indicates a goodwill impairment is more likely than not, we perform additional quantitative analyses. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing. For reporting units where a quantitative analysis is performed, we will perform a test measuring the fair values of the reporting units and comparing them to their aggregate carrying values, including goodwill. If the fair value is less than the carrying value of the reporting unit, an impairment is recognized for the difference, up to the carrying amount of goodwill.
We will estimate the fair values of our reporting units using a discounted cash flow method or a weighted combination of discounted cash flows and a market-based method. The discounted cash flow method includes assumptions about a wide variety of internal and external factors. Significant assumptions used in the discounted cash flow method include financial projections of free cash flow, including revenue trends, medical costs trends, operating productivity, income taxes and capital levels; long-term growth rates for determining terminal value beyond the discretely forecasted periods; and discount rates. Financial projections and long-term growth rates used for our reporting units will be consistent with, and use inputs from, our internal long-term business plan and strategies. Discount rates will be determined for each reporting unit and include consideration of the implied risk inherent in their forecasts. Our most significant estimate in the discount rate determinations involves our adjustments to the peer company weighted average costs of capital reflecting reporting unit-specific factors. We will not make any adjustments to decrease a discount rate below the calculated peer company weighted average cost of capital for any reporting unit. Company-specific adjustments to discount rates are subjective and thus are difficult to measure with certainty. The passage of time and the availability of additional information regarding areas of uncertainty with respect to the reporting units’ operations could cause these assumptions to change in the future. Additionally, as part of our quantitative impairment testing, we will perform various sensitivity analyses on certain key assumptions, such as discount rates, cash flow projections and peer company multiples to analyze the potential for a material impact. The market-based method requires determination of an appropriate peer group whose securities are traded on an active market. The peer group is used to derive market multiples to estimate fair value.
Valuation and Payback of Property and Equipment
Our Diagnostics segment purchases instruments and places them in fixed assets, where they remain, undepreciated, until they are placed with our customers under the agreement that they will repeatedly purchase assays (tests) which are utilized in the instrument. Each instrument placed in the portfolio represents an asset that we own. An estimate is made of the anticipated future revenue over the life of the instrument, based on the sale of assays, which is typically ten years. If the payback period of the initial investment in the asset is less than the ten-year life of the asset, we conclude that the assets have been properly recorded, and no write-down is necessary. We rely on third-party data that considers various data points and assumptions, including, but not limited to, the expected volume of assays which will be sold, anticipated growth rates and placements of instruments. Realization of the anticipated revenue is dependent on the current assumptions and forecasted models.
The customer is obligated to purchase assays during the placement period. However, since the customer is not obligated to purchase the instrument, and can return it at any time, we are exposed to a risk of loss to the extent the customer returns the instrument and discontinues assay purchases.
On September 30, 2022, the carrying value of our Diagnostic instruments was $5,087. A significant assumption included in the realization model is a placement rate of two instruments per month, per account manager.
The effect of a 50% reduction in the estimated annual placements of instruments would increase the payback period on September 30, 2022, by 0.49 years.
Changes to placement rates are not expected to decrease, nor do we expect that any decrease would be permanent.
Revenue Recognition and Liabilities Due to Customers
The nature of our Therapeutics business segment gives rise to variable consideration, including discounts and applicator (“trode”) returns. Credits are issued for unused shocks on returned trodes, which can be used toward the purchase of replacement trodes. When revenue
28
is recognized, a simultaneous adjustment for returns is estimated, reducing revenue. Estimated return credits are presented as a reduction to gross sales with the corresponding reserve presented as customer contract liabilities.
Variable consideration related to unused shock credits is calculated using the expected value method, which estimates the amount that is expected to be earned. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. Estimates of variable consideration are based upon historical experience and known trends. These estimated credits are non-refundable and may only be used towards the purchase of future trode refurbishments. This practice encourages refurbishment purchase prior to complete utilization of the previous trode, so the customer will always have a trode at hand with ample capacity to perform treatments.
The number of trodes returned by year is tracked against the number of trodes sold in that same year, creating a current experience rate. It is assumed that the ultimate return rate for the trodes is 98%. For annual calculations, it is assumed that the expected returns in the current year for each layer increase to the experience rate of the year immediately preceding it. Once the 98% is reached the layer is removed from the calculation. The annual incremental change in expected returns is multiplied by an average return credit amount, generating the current liability due to customers.
The average return credit is calculated by dividing the actual shock credits issued by the actual number of trodes returned. A variance in the assumed return rate compared to the actual rate would impact the estimate and potentially understate net sales (overestimated rate) or overstate net sales (underestimated rate) in any given year and create a corresponding misstatement of the liability due to customers.
On September 30, 2022, the estimated value of our Therapeutics customer contract liability was $418. If the expected return rate was increased by 2%, the effect on current year reduction in sales and increase in customer liability would have been approximately $26.
Results of Consolidated Operations
Revenue
Revenue for the three months ended September 30, 2022 was $4,776, compared to $23 for the three months ended September 30, 2021, an increase of $4,753 or 20,665%. The increase was primarily due to the inclusion of our PulseVet platform and Assisi products which had revenues of $4,682 consisting of consumables, instruments, trodes, and warranty services sold worldwide. Revenues from sales of cartridges from our TRUFORMA platform were $94 compared to $23, an increase of $71 or 309%.
Revenue for the nine months ended September 30, 2022 was $12,773, compared to $52 for the nine months ended September 30, 2021, an increase of $12,721 or 24,463%. The increase was primarily due to the inclusion of our PulseVet platform and Assisi products which had revenues of $12,531 consisting of consumables, instruments, trodes, and warranty services sold worldwide. Revenues from sales of cartridges from our TRUFORMA platform were $242 compared to $52, an increase of $190 or 365%.
We launched our TRUFORMA platform in March 2021, acquired PulseVet in October 2021, and acquired Assisi in July 2022. In general, we expect revenue to increase in subsequent periods as we increase our sales and marketing of the PulseVet platform and Assisi products and as additional assays are added to our TRUFORMA platform.
Cost of Revenue
Cost of revenue for the three months ended September 30, 2022 was $1,215, compared to $18 for the three months ended September 30, 2021, an increase of $1,197 or 6,650%. Cost of revenue primarily resulted from costs associated with sales of our PulseVet platform and Assisi products which totaled $1,171, as well as $44 from costs associated with sales of our TRUFORMA platform.
Cost of revenue for the nine months ended September 30, 2022 was $3,415, compared to $59 for the nine months ended September 30, 2021, an increase of $3,356 or 5,688%. Cost of revenue primarily resulted from costs associated with sales of our PulseVet platform and Assisi products which totaled $3,266, as well as $149 from costs associated with sales of our TRUFORMA platform.
We anticipate that costs of revenue will increase in 2022 in accordance with the increased revenue as described above.
Gross Profit Margin
Gross profit margin for the three months ended September 30, 2022 was $3,561 or 75%, compared to $5 for the three months ended September 30, 2021, an increase of $3,556.
29
Gross profit margin for the nine months ended September 30, 2022 was $9,358 or 73%, compared to a loss of $7 for the nine months ended September 30, 2021, an increase of $9,365.
The increase in gross profit for both the three and nine months ended September 30, 2022 resulted primarily from the inclusion of our PulseVet and Assisi platforms. In general, we believe gross margins will remain relatively unchanged due to a variety of factors, including the ability to effectively stimulate demand for certain of our products; management of the cost of components and outside manufacturing services; our ability to manage warranty costs effectively; shifts in the mix of products and services, or in the geographic, currency or channel mix; and fluctuations in exchange rates.
Research and Development
Research and development expense for the three months ended September 30, 2022 was $1,131, compared to $289 for the three months ended September 30, 2021, an increase of $842 or 291%. The increase was primarily driven by an increase in contracted expenses for research fees and trials as we continue to develop and test our next generation of TRUFORMA assays.
Research and development expense for the nine months ended September 30, 2022 was $1,801, compared to $1,008 for the nine months ended September 30, 2021, an increase of $793 or 79%. The increase was primarily driven by an increase in contracted expenses for research fees and trials as we continue to develop and test our next generation of TRUFORMA assays.
We anticipate that R&D costs will increase as we continue development of our additional assays.
Selling, General and Administrative
Selling, general, and administrative expense for the three months ended September 30, 2022 was $9,022, compared to $6,124 for the three months ended September 30, 2021, an increase of $2,898 or 47%. The increase was primarily driven by salaries and stock option expense associated with increased hiring campaigns, the inclusion of PulseVet and Revo headcount, PulseVet acquisition related intangible amortization, a significant increase in tradeshow/conference attendance, and an increase in marketing and advertising for PulseVet, Assisi, and Revo products.
Selling, general, and administrative expense for the nine months ended September 30, 2022 was $24,344, compared to $14,594 for the nine months ended September 30, 2021, an increase of $9,750 or 67%. The increase was primarily driven by salaries and stock option expense associated with increased hiring campaigns, the inclusion of PulseVet and Revo headcount, PulseVet acquisition related intangible amortization, increases in office expense, travel and tradeshow attendance/sponsorships associated with a lifting of COVID restrictions, our TRUFORMA launch and introduction of new assays, and marketing of our new line of PulseVet and Assisi products.
Net Loss
Our net loss for the three months ended September 30, 2022 was $4,995 compared to a loss of $6,346 for the three months ended September 30, 2021, an improvement of $1,351 or 21%.
Our net loss for the nine months ended September 30, 2022 was $14,206 compared to a loss of $15,093 for the nine months ended September 30, 2021, an improvement of $887 or 6%.
The net loss in each period was attributed to the matters described above. We expect to continue to record net losses in future periods until such time as we have sufficient revenue from product sales to offset our operating expenses.
30
Cash Flows
The following table shows a summary of our cash flows for the periods set forth below:
| Nine Months Ended | Nine Months Ended | |||||||||
| September 30, 2022 |
| September 30, 2021 |
| Change | ||||||
Cash used in operating activities | $ | (9,287) | $ | (9,373) | $ | 86 |
| (1)% | |||
Cash used in investing activities |
| (140,529) |
| (343) | $ | (140,186) |
| 40870% | |||
Cash provided by financing activities |
| 8 |
| 219,136 | $ | (219,128) |
| (100)% | |||
Increase in cash and cash equivalents |
| (149,808) |
| 209,420 | $ | (359,228) |
| (172)% | |||
Effect of exchange rate changes on cash |
| (49) |
| — | $ | (49) |
| 100% | |||
Cash and cash equivalents, beginning of period |
| 194,952 |
| 61,992 | $ | 132,960 |
| 215% | |||
Cash and cash equivalents, end of period | $ | 45,095 | $ | 271,412 | $ | (226,317) |
| (83)% |
Net cash used in operating activities for the nine months ended September 30, 2022, was $9,287, compared to $9,373 for the nine months ended September 30, 2021, an decrease in cash used of $86, or 1%. The decrease in cash used in operations primarily resulted from the decrease in our operating loss. Additionally, cash used in operations during the nine months ended September 30, 2022 included increased salary expenses and inventory purchases, offset in part by an increase in non-cash expenses including stock-based compensation expense and depreciation and amortization.
Net cash used in investing activities for the nine months ended September 30, 2022, was $140,529, compared to $343 for the nine months ended September 30, 2021, an increase of $140,186, or 40,870%. Cash used in investing activities during the nine months ended September 30, 2022 included $114,225 in investments in available for sale securities, $24,304 in acquisitions of Assisi and Revo, leasehold improvements, and expenditures to improve our ecommerce, internal sales, and accounting programs.
Net cash provided by financing activities for the nine months ended September 30, 2022, was $8, compared to $219,136 for the nine months ended September 30, 2021, a decrease of $219,128, or 100%. Cash provided by financing activities in 2021 primarily resulted from proceeds from the February 2021 public offering of our common shares, partially offset by stock issuance costs.
Liquidity and Capital Resources
We have incurred losses and negative cash flows from operations since our inception in May 2015. As of September 30, 2022, we had an accumulated deficit of $133,597. We have funded our working capital requirements primarily through the sale of our equity and equity-related securities and the exercise of stock options and warrants.
As of September 30, 2022, the Company had working capital (defined as current assets minus current liabilities) of $119,977.
Short Term Cash Requirements
We believe that our existing cash is sufficient to fund our expected short-term needs. We currently have fixed cash obligations in association with our building leases and quarterly inventory orders. We also have payment obligations associated with our on-going clinical studies and expect that we have sufficient cash to cover these requirements. We do not expect that PulseVet’s operations will require significant increases in our short-term cash needs.
Long Term Cash Requirements
We believe that our existing cash resources will be sufficient to fund our expected operational requirements through at least December 2024. We regularly evaluate our business plans and strategy. These evaluations often result in changes to our business plans and strategy, some of which may be material and significantly change our cash requirements. Ongoing business development activity may also require us to use some of our liquidity for an acquisition, and use of additional capital to fund newly acquired operations. If we raise additional funds by issuing equity securities, our existing security holders will likely experience dilution; and the incurring of indebtedness would result in increased debt service obligations and could require us to agree to operating and financial covenants that could restrict operations.
Our future capital requirements depend on many factors, including, but not limited to:
● | the costs and timing of our development and commercialization activities; |
31
● | the cost of manufacturing our existing and future products; |
● | the cost of marketing and selling our existing and future products including marketing, sales, service, customer support and distribution costs; |
● | the expenses needed to attract and retain skilled personnel; |
● | the costs associated with being a public company; |
● | the costs associated with additional business development or mergers and acquisitions activity, including acquisition-related costs, earn-outs or other contingent payments and costs of developing and commercializing any technologies to which we obtain rights; |
● | third-party costs associated with the development and commercialization of our existing and future products and the ability of our development partners to satisfy our requirements on a timely basis; |
● | the scope and terms of our business plans from time to time, and our ability to realize upon our business plans; and |
● | the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation. |
Outstanding Share Data
The only class of outstanding voting equity securities of the Company are the common shares. As of November 14, 2022:
● | there are 979,949,668 common shares issued and outstanding; |
● | there are stock options outstanding under our Stock Option Plan to acquire an aggregate of 77,345,224 common shares |
● | there are common share purchase warrants outstanding to acquire an aggregate of 197,917 common shares at an exercise price of $0.1500 per share issued in February 2020. |
● | there are common share purchase warrants outstanding to acquire an aggregate of 363,501 common shares at an exercise price of $0.1500 per share issued in April 2020. |
● | there are common share purchase warrants outstanding to acquire an aggregate of 10,000,000 common shares at an exercise price of $0.2201 per share issued in July 2022. |
● | there are common share purchase warrants outstanding to acquire an aggregate of 22,000,000 common shares at an exercise price of $0.2520 per share issued in July 2022. |
● | All of the currently outstanding warrants also have a “cashless exercise” feature which is applicable in certain circumstances. The cashless exercise feature could result in the potential issuance of common shares based upon the “in-the-money” value of the applicable warrants at the time of exercise of the applicable warrants. The number of the common shares that may be issued is not determinable. However, the number of common shares that are issuable is based upon a formula contained in the applicable warrants, which determines the number of common shares issuable by dividing the “in-the-money” value (based upon the then current market price, as provided in the applicable warrants) by the then current market price and multiplying this result by the number of common shares that are issuable under the applicable |
● | warrants pursuant to cash exercise. |
Recently Adopted Accounting Pronouncements
From time to time, the Financial Accounting Standards Board ("FASB") or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification ("ASC") are communicated through issuance of an
32
Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our Consolidated Financial Statements upon adoption.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Evaluation of Our Disclosure Controls
We maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive officer and our chief financial officer, to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and our principal financial officer concluded that, as of September 30, 2022, our disclosure controls and procedures were effective.
Changes in Internal Controls
There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the period covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
Item 1A. Risk Factors.
There have been no material changes in our risk factors from those previously disclosed in our annual report on Form 10-K for the year ended December 31, 2021 and our quarter report on Form 10-Q for the quarter and six months ended June 30, 2022.
33
Item 6. Exhibits.
The exhibits listed on the accompanying index to exhibits immediately preceding the exhibits are filed as part of, or hereby incorporated by reference into, this Quarterly Report.
EXHIBIT INDEX
Exhibit |
| Description |
---|---|---|
2.1 | ||
2.2 | ||
2.3 | ||
3.1 | ||
3.2 | ||
10.1+ | ||
10.2 | Lease Agreement, effective July 1, 2022 by and between Zomedica Inc. and Lebow 1031 Legacy, LLC | |
31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1* | ||
101.INS | Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL (1). | |
101.SCH | Inline XBRL Taxonomy Extension Schema Document (1). | |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document (1). | |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document (1). | |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document (1). | |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document (1). | |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.1) |
(1) | These interactive date files shall not be deemed filed for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under those sections. |
* This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.
+ | Indicates management contract or compensatory plan. |
34
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Zomedica Corp. | ||
November 14, 2022 | By: | /s/ Larry Heaton |
Name: | Larry Heaton | |
Title: | Chief Executive Officer | |
November 14, 2022 | By: | /s/ Ann Marie Cotter |
Name: | Ann Marie Cotter | |
Title: | Chief Financial Officer |
35
Exhibit 10.2
AGREEMENT OF LEASE
THIS AGREEMENT OF LEASE is made on this 9th day of October 2018, by and between GEORGIA MOTOR TRUCKING ASSOCIATION, INC., a Georgia not-for-profit corporation (hereinafter "Landlord") and REVO SQUARED, LLC, a Georgia limited liability company (hereinafter "Tenant").
WITNESSETH:
ARTICLE 1 PREMISES
1.01 - In consideration of the rent hereinafter reserved and of the covenants hereinafter contained, Landlord does hereby lease to Tenant, and Tenant does hereby lease from Landlord, that certain space located on the First Floor of the Building, shown on the floor plan attached hereto as Exhibit "A", and designated as Suite 100 ("Premises"). The total square footage of the Premises shall be 4,626 rentable square feet, which includes a common area factor of 1.10. The term "Building" shall mean the office building located at 2060 Franklin Way, Marietta, Georgia 30067 (Cobb County) which, along with all exterior grounds encompassing the property upon which the Building lies shall be referred to as the "Project".
ARTICLE 2 TERM
2.01 - The term of this Lease (the "Term") shall be effective as of November 10, 2018 (the "Commencement Date") and shall terminate at 12:00 o'clock midnight, local time, on the 31st day of December 2023 which completes 61 months, 20 days of tenancy hereunder (the "Expiration Date").
2.02 - This Lease shall be effective and enforceable as between the parties hereof upon its execution and delivery. If delivery of possession of the Premises shall be delayed beyond the Commencement Date, this Lease shall not be void or voidable, nor shall Landlord shall be liable to Tenant for any damage resulting from such delay; however Tenant's obligation to pay Basic Rent, as hereinafter defined (unless such delay is a "Tenant Delay" as herein defined), shall be suspended and abated until possession of the Premises is delivered to Tenant (as more specifically set forth in Section 2.03). In the event of such a delay, it is understood and agreed that the Commencement Date shall be postponed until delivery of possession and that the Expiration Date shall be correspondingly extended and the same shall memorialized in Exhibit E ("Commencement Date Agreement") herein attached. In the event the Premises is delivered in condition ready for occupancy prior to the Commencement Date, Tenant may take possession of the Premises without any obligation to pay Basic Rent (as defined in Article 3 hereof), but otherwise subject to all of the terms, covenants, warranties and representations of Tenant contained in this Lease.
For the purposes herein, a "Tenant Delay" shall be defined as delays due to (i) Tenant's failure to promptly review and approve plans or finish selections, (ii) Tenant's change orders or additions to the work, or (iii) Tenant's ordering of long lead-time item as part of the work. With respect to (ii) and (iii), Landlord shall have obligation to notify Tenant within three (3) days following any change order or addition, or long lead item requested by Tenant whether such will delay the target completion date, and estimated delay period. Tenant will have two (2) days to instruct Landlord to proceed with the change, addition or long lead item (accepting as Tenant Delay), or abandon the change, addition, or long lead item in order to avoid a Tenant Delay.
2.03 - The Premises shall be considered in a condition ready for occupancy by Tenant when Landlord's construction coordinator supervising construction of the improvements described in Exhibit "B" shall certify in writing to Landlord (i) such improvements have been substantially completed, and (ii) a certificate of occupancy has been obtained. Taking of possession by Tenant shall be deemed conclusively to establish that Landlord's construction obligations with respect to the Premises have been substantially completed in accordance with the its obligations under this Lease and that the Premises, to the extent of Landlord's construction obligations with respect thereto, are in good and satisfactory condition and Tenant otherwise accepts same in its then "AS IS" condition, except for such punchlist items, if any, as may have been identified by Tenant and Landlord upon joint walk-thru no later than three (3) days following possession by Tenant, and completed within thirty (30) days thereafter.
ARTICLE 3 RENT
3.01 - Tenant hereby covenants and agrees to pay to Landlord as rent for the Premises (all of which is collectively referred to as "Rent"): (a) an annual basic rent ("Basic Rent") in accordance with the schedule set forth in Section 3.02 below, in advance on the first day of each month during each calendar year, or portion thereof (with appropriate adjustment for any calendar year which does not fall totally within the Term), during the Term; provided, however, that the installment of Basic Rent payable for the first full calendar month, that portion of Basic Rent which is payable for such month) shall be due and payable on
1
the execution of this Lease; and (b) additional rent ("Additional Rent") in the amount of any payment referred to as such in any portion of this Lease which accrues while this Lease is in effect (which shall include any and all charges or other amounts which Tenant is obligated to pay Landlord under this Lease, other than Basic Rent.)
3.02 - The Basic Rent schedule is as follows:
3.03 - Basic Rent and all Additional Rent as provided for under this Lease shall be paid promptly when due, in cash or by check, in Lawful money of the United States of America, without notice or demand and without deduction, diminution, abatement, counterclaim or set off of any amount or for any reason whatsoever, payable to Landlord and delivered to 2060 Franklin Way, Suite 200, Marietta GA 30067 or to such other person and place as may be designated by written notice from Landlord to Tenant from time to time. If Tenant shall present to Landlord more than twice during the term checks not honored by the institution upon which they are issued, Landlord may thereafter require future payments of Rent and other sums payable via certified or cashier's check.
3.04 - Other remedies for non-payment of Rent notwithstanding, any installment of Rent which is not paid within five (5) days after the due date shall be subject, at Landlord's option each month, to a late charge equal to five percent (5%) of the amount due, which shall be payable as Additional Rent. Any installment of Basic Rent or Additional Rent not paid within thirty (30) days from the date due shall accrue interest at the rate of four percentage points higher than the rate announced by Bank of America (or its successor) from time to time as its prime rate (the "Prime Rate") (but in no event higher than the maximum rate allowed by law) until paid in full, which interest shall be deemed Additional Rent. No payment by Tenant or receipt by Landlord of a lesser amount than the monthly installments of Rent herein stipulated shall be deemed to be other than on account of the earliest stipulated Rent nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check for payment without prejudice to Landlord's right to recover the balance of such Rent or to pursue any other remedy provided in this Lease.
3.05- Simultaneously with the execution of this Lease, Tenant shall deposit with Landlord the sum of Six Thousand and Five Hundred no/100 Dollars ($6,500.00) as a Security Deposit. The Security Deposit (which shall not bear interest to Tenant) shall be considered as good faith security for the payment and performance of the obligations, covenants, conditions and agreements contained herein. The Security Deposit shall not constitute an advance payment of any amounts owed by Tenant under this Lease, or a measure of damages to which Landlord shall be entitled upon a breach of this Lease by Tenant or upon termination of this Lease. In the event Tenant fails to perform or observe any of the agreements, covenants, conditions and provisions of this Lease to be performed or observed by it, then, at Landlord's option, Landlord may, but shall not be obligated to, apply the Security Deposit, or so much thereof as may be necessary, to remedy any such failure by Tenant. Tenant shall immediately upon request pay to Landlord any sum necessary to restore the Security Deposit to the full amount specified above. Any remaining portion of the Security Deposit shall be returned to Tenant within twenty (20) days after the termination of this Lease. In the event of a sale, assignment, or other transfer of Landlord's interest in the Premises, or a lease by Landlord of its interest in the Project, Landlord shall have the right to transfer the within described Security Deposit to the transferee, and Landlord shall be relieved of all liability to Tenant for the return of such Security Deposit. Tenant shall look solely to the transferee for the return of said Security Deposit. The Security Deposits shall not be mortgaged, assigned or encumbered by Tenant. In the event of a permitted assignment under this Lease by Tenant, the Security Deposit shall be held by Landlord as a deposit made by the permitted assignee and Landlord shall have no further liability with respect to the return of said Security Deposit to the original Tenant.
ARTICLE 4 USE OF PREMISES
4.01 - Tenant covenants to use the Premises for general office use and light assembly subject to and in accordance with all applicable zoning and other governmental regulations. Tenant, at its own expense, shall comply with and promptly carry out all orders, requirements or conditions imposed by the ordinances, laws and regulations of all of the governmental authorities having jurisdiction over the
2
Premises, which are occasioned by or required in the conduct of Tenant's business within the Premises and to obtain all licenses, permits and the like required to permit Tenant to occupy the Premises. Tenant shall not permit the Premises, or any part thereof, to be used for any disorderly, unlawful or hazardous purpose, nor as a source of annoyance or embarrassment to Landlord or other tenants, nor for any purpose other than herein before specified, nor for the manufacture of any commodity therein, without the prior written consent of Landlord. Tenant shall not overload the floor load capacity for the Building. The subject property is zoned light industrial which accommodates Tenant's intended use.
4.02 - Tenant accepts the Premises and the rest of the Project from Landlord in the improved condition as described in Exhibit "B" attached hereto (said improvements to be performed at Landlord's sole cost and expense) and incorporated herein by this reference, Tenant agreeing that such condition is suited for the uses intended by Tenant.
ARTICLE 5 PROPERTY TAX INCREASES
5.01 - For purposes of this Article 5 (and the balance of this Lease) the following definitions shall apply:
(a)"Base Year": shall mean the calendar year 2019.
(b)"Base Year Tax Costs" shall mean the actual Tax Costs incurred by Landlord for the Base Year.
(c)"Comparison Year" shall mean each calendar year after the Base Year, all or any portion of which falls within the Term.
(d)"Tax Costs" shall mean the aggregate of the real estate taxes, assessments and other governmental charges and levies, general and special, ordinary and extraordinary, foreseen and unforeseen, of any kind or nature whatsoever (including assessments for public improvements or benefits and interest on unpaid installments thereof) which may be levied, assessed or imposed or become liens upon the Project (or permanent improvements comprising the same), or which arise out of the use, occupancy or possession of the Project (or the permanent improvements comprising the same) from time to time, plus any reasonable consultants' fees or attorneys' fees incurred with respect to issues or concerns involving any of the foregoing taxes, including any amounts expending by Landlord contesting any of such taxes. The term "Tax Costs" shall not, however, include inheritance, estate, succession, transfer, gift, franchise, corporation, income or profit tax imposed upon Landlord, nor penalties or interest imposed upon Landlord for Landlord's delinquent payment of any taxes; provided, however, that if at any time during the term of this Lease the methods of taxation prevailing at the commencement of the Term shall be altered so that in addition to or in lieu of or as a substitute for the whole or any part of the taxes now levied, assessed or imposed on real estate as such there shall be levied, assessed or imposed a tax on the rents received from the Project; or a license fee measured by the rents receivable by Landlord from the Project; or a tax or license fee imposed upon Landlord which is otherwise measured by or based in whole or in part upon the Project or any portion thereof, then such tax or fee shall be included in the computation of Tax Costs, computed as if the amount of such tax or fee so payable were that part due if the Office Parcel were the only property of Landlord subject thereto.
(e)"Tenant's Share" shall mean the proportion that the rentable square feet in the Premises (as referenced in Article 1) bears to the total rentable square footage in the Project (19,753) which is deemed to be twenty-three and 42/100 percent (23.42%). In the event of any change in the rentable square footage in the Premises or in the Project due to a physical change or reconfiguration of space, Tenant's Share shall be adjusted to reflect such change or event on a prorated, daily basis.
5.02 - If the Tax Costs paid or incurred by Landlord in any Comparison Year increase over the Base Year Tax Costs, Tenant shall pay, as additional rent, Tenant's Share of the increase. Tenant's Share of increases in Tax Costs shall be prorated for any partial Comparison Year which falls within the Lease Term. Notwithstanding anything contained in this Article 5, the Basic Rent payable by Tenant shall in no event be less than the Basic Rent specified in Article 2 contained herein.
5.03 - Landlord shall deliver to Tenant a statement showing Landlord's reasonable estimate of the Tax Costs for each Comparison Year and the amount of Tenant's Share of any increase in Tax Costs based on such estimate. Commencing as of the first (1st) day of each Comparison Year, Tenant shall pay to Landlord, as additional rent, at the times and in the manner provided herein for the payment of Base Rent, one-twelfth (1/12) of Tenant's Share of any increases as shown by Landlord's statement. If Landlord has not furnished a statement to Tenant on or before January 1 of a Comparison Year, then Tenant shall continue to pay on the basis of the prior year's estimate until such time as Landlord furnishes Landlord's statement whereupon either (i) the deficiency, if any, with respect to the amount of Tenant's Share of any increases for each calendar month or fraction thereof that has already elapsed in such Comparison Year shall be paid
3
by Tenant with the next monthly installment of Base Rent or (ii) the overpayment, if any, shall be credited and applied against the next payment of Rent due of Tenant.
5.04 - Within ninety (90) days after the end of each Comparison Year (including the Comparison Year in which the Lease terminates or expires) or within thirty (30) days after a final determination of Tax Costs in the event of a tax appeal, whichever is later, Landlord shall deliver to Tenant a final statement of the Tax Costs for such Comparison Year. Within thirty (30) days of delivery of such final statement, Tenant shall pay Landlord the amount due for Tenant's Share of any increases in the Tax Costs. Objections by Tenant shall not excuse or abate Tenant's obligation to make the payments required under this provision pending the resolution of Tenant's objection. Any credit due Tenant for overpayment of Tenant's Share of any increases in the Tax Costs shall be credited against the next payment of Rent due of Tenant; provided, however, that overpayment for the Comparison Year in which the Lease terminates or expires shall be refunded to Tenant.
5.05 - Landlord shall have the sole, absolute and unrestricted right (but not the obligation) to contest and/or compromise the validity or amount of any Tax Costs by appropriate proceedings. Landlord shall have the right (but not the obligation), if permitted by law, to make installment payments of any assessments levied against the Project, and in such event, Tenant's Share of the Tax Costs shall be computed upon the installments and interest thereon paid by Landlord during the applicable period. Landlord shall reimburse Tenant for the Tenant's Share of any refund of any Tax Costs for which Tenant paid Tenant's Share.
5.06 - Tenant shall pay (or reimburse Landlord upon demand if the same are levied against Landlord or the Building or any portion thereof), before delinquency, any and all taxes (other than net income taxes, estate or inheritance taxes, or franchise taxes of Landlord) whether or not now customary or within the contemplation of the parties hereto, which are: (i) payable upon, measured by or reasonably attributable to the cost or value of Tenant's equipment, furniture, fixtures, alterations, additions or improvements (whether constructed by Landlord or Tenant) and other personal property located in the Premises or by the cost or value of any leasehold improvements made in or to the Premises by or for Tenant, regardless of whether title to such improvement shall be in Landlord or Tenant; (ii) payable upon, measured by or reasonably attributable to the Rent payable hereunder, or any component thereof, including, without limitation, any gross income tax or excise tax levied by the City of Smyrna, the County of Cobb, the State of Georgia, the Federal Government or any other federal, state, county, municipal or other governmental body with respect to the receipt of such rent; (iii) payable upon or with respect to the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises or any portion thereof; and (iv) payable upon this transaction or any document to which Tenant is a party creating or transferring an interest or an estate in the Premises.
ARTICLE 6 REPAIRS AND MAINTENANCE
6.01 - Subject to the provisions hereinafter contained with regard to damage by fire or other casualty and Article 16, all repairs, alterations or additions that affect the Project's structural components or the Project's mechanical, electrical and plumbing systems shall be made solely by Landlord or its contractor. In the event of any damage to such components or systems caused by Tenant or Tenant's agents, contractors or employees, the cost of repair or restoration of such damage shall be paid for solely by Tenant in an amount equal to Landlord's costs plus ten percent (10%) for administrative cost recovery. Landlord shall make such repairs to Building Standard improvements as may be deemed necessary by Landlord for normal maintenance operations and Landlord shall not otherwise be obligated to make improvements to, or repairs of, the Premises; provided, however, Landlord shall, at Tenant's expense, make such improvements to, or repairs of, the Premises as Tenant shall request in writing, at a cost equal to the costs incurred by Landlord in such maintenance or such repairs, plus an additional charge of ten percent (10%) for administrative cost recovery. Landlord shall not be liable to Tenant for any damage or inconvenience and Tenant shall not be entitled to any abatement or reduction of rent by reason of any repairs, alterations or additions made by Landlord under this Lease, so long as said repair, alteration or addition does not unreasonably restrict Tenant's use of the Premises. Landlord shall not be required to make any repairs or improvements to the Premises except structural repairs necessary for safety and tenantability. To the fullest extent permitted by law, Tenant hereby waives all rights to make repairs at the expense of Landlord or in lieu thereof to vacate the Premises as may be provided by any law, statute or ordinance now or hereafter in effect. Landlord has no obligation and has made no promise to alter, remodel, improve, repair, decorate or paint the Premises or any part thereof, except as specifically and expressly herein set forth.
6.02 - Subject to Section 6.01, Tenant shall at its own cost and expense, keep the Premises and all leasehold improvements in a condition similar to the condition as of the Commencement Date, normal wear and tear accepted.
ARTICLE 7 LANDLORD'S SERVICES
7.01 - Landlord covenants and agrees that it shall furnish without additional charge: (a) heat and
4
airconditioning systems sufficient to operate and maintain the Premises at a reasonably comfortable temperature commensurate with commercial buildings of like grade and class in Atlanta, GA, (b) hot & cold water for restrooms and kitchen area, and (c) electrical service sufficient for Tenant's operations utilizing building standard load of office computers and office equipment. Tenant hereby acknowledges and agrees that Landlord shall not be liable in any way for any damage or inconvenience caused by the cessation or interruption of heating, airconditioning, and/or electricity, occasioned by fire, accident, strikes, necessary maintenance, alterations or repairs, or other causes beyond Landlord's control and Tenant shall not be entitled to any abatement or reduction of Rent by reason therefrom. During non-working hours in winter months, Tenant shall take reasonable care to maintain the heat thermostat at a minimum range to prevent pipes within the Premises to freeze. Landlord shall maintain the mechanical systems of the premises and replace expired lighting ballasts and/or bulbs. Landlord shall make plumbing repairs at Landlord's expense (toilets and sinks) provided such repairs are not clogs necessitated by Tenant's negligence (i.e. flushing or disposing of any articles that are known not to be placed in drains or toilets). In said event, Tenant shall be notified of this cause and shall reimburse Landlord for the repair (Per Exhibit C #16 herein attached).
7.02 - Landlord reserves the right to erect, use, connect to, maintain and repair pipes, ducts, conduits, cables, plumbing, vents and wires in, to and through the Premises as and to the extent that Landlord deems necessary or appropriate for the proper operation and maintenance of the Project (including the servicing of other tenants in the Project) and the right at all times to transmit water, heat, air-conditioning and electric current through such pipes, ducts, conduits, cables, plumbing, vents and wires. Notwithstanding the foregoing, Landlord's exercise of rights in connection herewith shall not make Tenant's use of the Premises substantially unfeasible for the operations of Tenant's business, or materially adversely affect access to the Premises.
ARTICLE 8 TENANT'S AGREEMENT
8.01 - Tenant covenants and agrees: (a) not to obstruct or interfere with the rights of other tenants, or injure or annoy them or those having business with them or conflict with them, or conflict with the fire laws or regulations, or with any insurance policy upon said Property or any part thereof, or with any statutes, rules or regulations now existing or subsequently enacted or established by the local, state or federal governments and Tenant shall be answerable for all nuisances caused or suffered on the Premises, or caused by Tenant in the Project, or on the approaches thereto; (b) not to strip, overload, damage or deface the Premises, exterior covered walkways, stairways, parking facilities or other public areas of the Project, or the fixtures therein or used therewith, nor to permit any hole to be made in any of the same; (c) not to suffer or permit any trade or occupation to be carried on or use made of the Premises which shall be unlawful, noisy, offensive, or injurious to any person or property, or such as to increase the danger of fire or affect or make void or voidable any insurance on the Project, or which may render any increased or extra premium payable for such insurance, or which shall be contrary to any law or ordinance, rule or regulation from time to time established by any public authority; (d) not to place upon the interior or exterior of the Building, or any window or any part thereof or door of the Premises, any placard, sign, lettering, window covering, except such and in such place and manner as has been herein approved and specifically noted in Special Stipulations; (e) to conform to all rules and regulations from time to time established by the appropriate insurance rating organization and to all reasonable rules and regulations from time to time established by Landlord, including those attached as Exhibit "C" hereto; (f) to be responsible for the cost of removal of Tenant's bulk trash at time of move-in, during occupancy-and move-out; (g) contract for professional janitorial service for not less than twice weekly; (h) not to conduct nor permit in the Premises either the generation, treatment, storage or disposal of any hazardous substances and materials or toxic substances of any kind as described in the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended (42 U.S.C. Section 9601 et seq.), the Resource Conservation and Recovery Act, as amended (42 U.S.C. 6901 et seq.), any regulations adopted under these acts, or any other present or future federal, state, county or local laws or regulations concerning environmental protection, and Tenant shall prohibit its assignees, subtenants, employees, agents and contractors (collectively: "Permitees") from doing so; and Tenant shall indemnify, defend and hold Landlord and its agents harmless from all foreseeable and unforeseeable, direct or consequential losses, costs, damages, liabilities, fines, prosecutions, judgments, litigation, and expenses, including but not limited to, clean-up costs, court costs and reasonable attorneys' fees actually incurred arising out of any violation of the provisions of this Article by Tenant or its Permitees.
ARTICLE 9 ALTERATIONS
9.01 -Tenant shall not make any alterations, additions, or other improvements in or to the Premises or install any equipment of any kind that shall require any alterations or additions or affect the use of the Building's water system, heating system, plumbing system, air-conditioning system, electrical system or other mechanical system, or install any telephone antennae on the roof, in the windows, or upon the exterior of the Building without prior written consent of Landlord. If any Tenant makes such alterations or additions without Landlord's consent, Landlord may correct or remove them, and Tenant shall be liable for any and
5
all costs and expenses incurred by Landlord in the correction or removal of such work. If any alterations or additions are performed by Tenant or its contractor, Tenant shall pay Landlord a fee of ten percent (10%) of the total cost of the work to be performed, payable five percent (5%) prior to the beginning of the work and the remaining five percent (5%) upon completion of the work. Such fee is to compensate Landlord for coordinating Tenant's contractor's use of the Building's systems and for access to the electrical, mechanical and telephone closets, as necessary. As a further condition of Landlord's consent to the use of Tenant's contractor, Tenant or Tenant's contractor must evidence insurance coverage to include: (a) Worker's Compensation coverage and (b) Comprehensive General Liability and Property Damage insurance in the amount of not less than Two Million Dollars ($2,000,000.00) in the aggregate. All work with respect to such alterations and additions shall be done in a good and workmanlike manner and diligently prosecuted to completion to the end that Premises shall at all times be a complete unit except during the period necessarily required for such work. Tenant shall not permit a mechanic's lien(s) to be placed upon the Premises, the Building or the Building as a result of any alterations or improvements made by it and agrees, if any such lien be filed on account of the acts of Tenant, promptly to pay the same. If Tenant fails to discharge such lien within ten (10) days of filing, then, in addition to any other right or remedy of Landlord, Landlord may, at its election, discharge the lien. Tenant shall pay on demand any amount paid by Landlord for the discharge or satisfaction of any such lien, and all attorneys' fees and other costs and expenses of Landlord incurred in defending any such action or in obtaining the discharge of such action or in obtaining the discharge of such lien, together with all necessary disbursements in connection therewith. Tenant hereby expressly recognizes that in no event shall it be deemed the agent of Landlord and no contractor of Tenant shall by virtue of its contract be entitled to assert any lien against the Premises, Building or Project. All alterations or additions shall become a part of the realty and surrendered to Landlord upon the expiration or termination of this Lease, unless Landlord shall at the time of its approval of such work require removal or restoration on the part of Tenant as a condition of such approval.
ARTICLE 10 HOLD HARMLESS
10.01 - Unless occasioned by Landlord's gross negligence, Landlord shall not be liable for any damage to, or loss of, property in the Premises belonging to Tenant, its employees, agents, visitors, licensees or other persons in or about the Premises, or for damage or loss suffered by the business of Tenant, from any cause whatsoever, including, without limiting the generality thereof, such damage or loss resulting from fire, steam, smoke, electricity, gas, water, rain, ice or snow, which may leak or flow from or into any part of the Premises, or from the breakage, leakage, obstruction or other defects of the pipes, wires, appliances, plumbing, air-conditioning or lighting fixtures of the same, whether the said damage or injury results from conditions arising upon the Premises or upon other portions of the Building of which the Premises are a part, or from other sources. In the event of Landlord gross negligence, Landlord's liability shall remain subject to Section 12.05 below. Landlord shall not be liable in any manner to Tenant, its agents, employees, invitees or visitors for any injury or damage to Tenant, Tenant's agents, employees, invitees or visitors, or their property, caused by the criminal or intentional misconduct, or by any act or neglect of third parties or of Tenant, Tenant's agents, employees, invitees or visitors, or of any other tenant of the Building. Tenant covenants that no claim shall be made against Landlord by Tenant, or by any agent or servant of Tenant, or by others claiming the right to be in the Premises or in the Building through or under Tenant, for any injury, loss or damage to the Premises or to any person or property occurring upon the Premises from any cause other than the negligence of Landlord. In no event shall Landlord be liable to Tenant for any consequential damages sustained by Tenant arising out of the loss or damage to any property of Tenant.
10.02 - Tenant covenants and agrees to save Landlord and Landlord's agent harmless and indemnified, and to defend Landlord and Landlord's agent from all loss, damage, liability or expense of any kind, including without limitation attorneys' fees and court costs incurred, suffered or claimed by any person whomsoever, or for any damage or injury to any persons or property from any cause whatsoever, by reason of the use or occupancy by Tenant, its agents, employees, invitees or visitors of the Premises, or of the Building unless caused by the gross negligence of Landlord.
10.03 - It is understood that employees of Landlord are prohibited as such from receiving any packages or other articles delivered to the Building for Tenant and that should any such employee receive any packages or articles, he or she in so doing shall be the agent of Tenant and not of Landlord.
10.04 - The provisions of this Article 10 shall survive the expiration or sooner termination of the Term.
ARTICLE 11 LIEN ON TENANT'S PROPERTY
11.01 - INTENTIONALLY DELETED (Landlord waives right to lien on Tenant's Property as a security interest
6
ARTICLE 12 INSURANCE
12.01 - Tenant shall, at its cost and expense, obtain and maintain at all times during the Term, for the protection of Landlord and Tenant, Public Liability Insurance (Comprehensive General Liability or Commercial General Liability) including Contractual Liability Insurance, with a combined personal injury and property damage limit of not less than One Million Dollars ($1,000,000) for each occurrence and not less than Two Million Dollars ($2,000,000) in the aggregate, insuring against liability of Tenant and its representatives arising out of and in connection with Tenant's use or occupancy of the Premises. Landlord shall be named as additional insured.
12.02 - Tenant shall, at its cost and expense, obtain and maintain at all times during the Term, fire and extended coverage insurance on its contents (personalty), including any leasehold improvements made by Tenant in an amount sufficient so that no co-insurance penalty shall be invoked in case of loss.
12.03 - Insurance companies licensed to do business in the jurisdiction where the Building is located shall issue all insurance required under this Lease. Such companies shall have a policyholder rating of at least "A" and be assigned a financial size category of at least "Class X" as rated in the most recent edition of "Best's Key Rating Guide" for insurance companies. Each policy shall contain an endorsement requiring ten (10) days written notice from the insurance company to Landlord before cancellation or any change in the coverage, scope or amount of any policy. Each policy, or a certificate showing it is in effect, together with evidence of payment of premiums, shall be deposited with Landlord on or before the Commencement Date, and renewal certificates or copies of renewal policies shall be delivered to Landlord at least ten (10) days prior to the expiration date of any policy.
12.04 - If any of Tenant's insurance policies shall be canceled or cancellation shall be threatened or the coverage thereunder reduced or threatened to be reduced in any way because of the use of the Premises or any part thereof by Tenant or any assignee or subtenant of Tenant or by anyone Tenant permits on the Premises, and if Tenant fails to remedy the condition within forty-eight (48) hours after notice thereof, Landlord may at its option, either terminate this Lease or enter upon the Premises and attempt to remedy such condition, and Tenant shall promptly pay the cost thereof to Landlord. Landlord shall not be liable for any damage or injury caused to any property of Tenant or of others located on the Premises from such entry.
12.05 - All policies covering real or personal property which either party obtains affecting the Premises shall include a clause or endorsement denying the insurer any rights of subrogation or recovery against the other party to the extent rights have been waived by the insured before the occurrence of injury or loss. Anything in this Lease to the contrary notwithstanding, Landlord and Tenant each hereby waives any and all rights of recovery, claim, action or cause of action, against the other, its agents, servants, partners, shareholders, officers or employees, for any loss or damage that may occur to the Premises, the Project or any improvements thereto or thereon, or any personal property of such party therein or thereon, by reason of fire, the elements, or any other cause which is covered or which should be covered by policies of insurance obtained or which should be or have been obtained pursuant to this Lease, to the extent of the injury or loss covered thereby assuming that any deductible shall be deemed to be insurance coverage, regardless of cause or origin, including negligence of the other party hereto, its agents, officers, partners, shareholders, servants or employees.
12.06 - Any insurance to be carried by Tenant under this section may be provided by a policy or policies of blanket insurance, provided, however, that the Premises is a scheduled location thereunder and the amount of the total insurance allocated to the Premises or the Building, as the case may be, shall be such as to furnish protection equivalent to a separate policy satisfying the requirements of this Section, and provided further in all other respects every such blanket policy or policies shall comply with the other provisions of the Lease. If at any time Tenant fails to maintain the insurance it is required to provide hereunder or shall fail to deliver such certificates or receipts as herein required, Landlord at its options, after five (5) business days prior written notice to Tenant, may obtain such insurance for a term of up to one (1) year at Tenant's sole cost and expense.
ARTICLE 13 ASSIGNMENT & SUBLETTING
13.01 - Tenant shall not sublet any part of the Premises, nor assign this Lease or any interest herein, without the prior written consent of Landlord. Any sublease or assignment made without Landlord's consent shall be void. In determining whether to grant or withhold consent to a proposed assignment or sublease, Landlord may consider, and weigh, any factor it deems relevant. Without limiting what may be construed as a factor considered by Landlord, Tenant agrees that the following are examples of reasons Landlord may withhold its consent: (i) the proposed subtenant or assignee may in Landlord's judgment unreasonably burden the Building, its amenities or services; (ii) the financial statements or the business experience of the proposed assignee or subtenant are not satisfactory to Landlord given the obligations being undertaken by such assignee or subtenant in connection with such assignment or sublease; or (iii) the proposed use of the Premises conflicts in an adverse manner with other uses within the Building; or (iv) the prospective assignee
7
or subtenant is an existing tenant of Landlord's in the Project and in Landlord's judgment such sublease or assignment will adversely affect Landlord's lease relationship with such tenant. Consent by Landlord to one assignment or sublease shall not destroy or waive this provision and all later assignments and subleases shall likewise be made only upon prior written consent of Landlord. If a sublease or assignment is consented to by Landlord, any subtenants or assignees shall become liable directly to Landlord for all obligations of Tenant hereunder without relieving or in any way modifying Tenant's liability hereunder.
13.02 - If Tenant desires to assign this Lease or sublet the Premises or any part thereof, Tenant shall give Landlord written notice at least twenty (20) days in advance of the date on which Tenant desires to make such assignment or sublease, which notice shall specify: (a) the name and business of the proposed assignee or subtenant; (b) the amount and location of the space in the Premises affected; (c) the proposed effective date of the subletting or assignment; and (d) the proposed rental to be paid to Tenant by such subtenant or assignee. If Tenant shall give such notice, Tenant shall pay on demand Landlord's reasonable actual costs, including attorneys' fees incurred, to consider and as necessary to document such transaction, but in no event less than $750.00. If Tenant notifies Landlord of Tenant's intent to sublease or assign this Lease, then Landlord shall, within fifteen (15) days from receipt of such notice, notify Tenant in writing that Landlord (a) consents to such proposed assignment or subletting; (b) denies its consent (and, Landlord shall fail to notify Tenant in writing of such election within said fifteen (15) day period, then Landlord shall be deemed to have elected to have granted such consent pursuant to clause (a) immediately preceding); or (c) elects to cancel this Lease, or to reduce the Premises by the area requested to be subleased or assigned if the area is less than the entire Premises (provided, however, that Landlord may only elect to cancel this Lease if the proposed assignment or sublease is for all or substantially all of the Premises and for all or substantially all of the then remaining Term hereof, and only if the proposed assignee or subtenant is a third party not affiliated with Tenant). If Landlord's election is to cancel or to reduce the area of the Premises as provided in the foregoing clause (c) (such election by Landlord being referred to herein as "Landlord's Modification Election"), then Tenant shall have ten (10) days from receipt of Landlord's Modification Election to notify Landlord of Tenant's acceptance of such cancellation or reduction or of Tenant's desire to remain in possession of the Premises under this Lease for the remainder of the Tenn. If Tenant fails to notify Landlord of Tenant's election to accept termination or reduction or to continue as Tenant hereunder, then such failure shall be deemed an election to terminate or have the area of the Premises reduced, as the case may be, in accordance with Landlord's Modification Election, and such termination or reduction shall be effective at the later of (y) the end of the ten (10) day period provided for above, or (z) the proposed effective date of the proposed assignment or subletting in question.
13.03 - If Landlord gives its consent to any such assignment or sublease, then after first deducting from the gross subletting or assignment rentals all reasonable costs and expenses incurred by Tenant in connection with obtaining, procuring or effecting such assignment or sublease (including for example only brokerage fees or commissions, legal fees, and costs and expenses of preparing the affected portion of the Premises for occupancy by the assignee or subtenant), Tenant agrees to pay to Landlord an amount equal to fifty percent (50%) of any such net amount or other cost to the assignee or subtenant for all or any portion of the Premises over and above the Rent payable by Tenant for such space shall be due and payable, and shall be paid, to Landlord. If this Lease is canceled, the area of the Premises is reduced, or a sublease or assignment is made as herein provided, Tenant shall pay Landlord a charge equal to the reasonable actual costs incurred by Landlord for all of the necessary legal and accounting or subletting, as the case may be. Any physical alterations necessary with respect to any such assignment or subletting of the Premises shall be subject to the provisions of this Lease regarding alterations and shall be at Tenant's sole cost and expense, unless such physical alterations are made after a Landlord's Modifications Election is made with respect thereto, in which event Landlord shall be solely responsible for such cost and expense. No acceptance by Landlord of any rent or any other sum of money from any assignee, subtenant, or other category of transferee shall release Tenant from any of its obligations under this Lease or be deemed to constitute Landlord's consent to such assignment, sublease or transfer.
13.04 - The sale or transfer of Tenant's voting stock (if a corporation) or a partnership interest (if a partnership) or member interest (if a limit liability company) in Tenant resulting in the transfer of control of a majority of such stock or interest, or the occupancy of the Premises by any successor firm of Tenant or by any firm into which or with which Tenant may become merged or consolidated shall be deemed an assignment of this Lease requiring the prior written consent of Landlord.
13.05 - The joint and several liability of Tenant named herein and any immediate and remote successor in interest of Tenant (by assignment or otherwise), and the due performance of the obligations of this Lease on Tenant's part to be performed or observed, shall not in any way be discharged, released or impaired by any (i) agreement which modifies any of the rights or obligations of the parties under this Lease, other than an agreement to which Landlord is a signatory which expressly provides to the contrary, (ii) stipulation which extends the time within which an obligation under this Lease is to be performed, (iii) waiver of the performance of an obligation required under this Lease, or (iv) failure to enforce any of the obligations set forth in this Lease; provided, however, that (a) in the case of any modification of this Lease made after the date of an assignment or other transfer of this Lease by Tenant, if such modification increases or enlarges the obligations of Tenant or reduces the rights of Tenant, then Tenant named herein and each
8
respective assignor or transferor shall not be liable under or bound by any such increase, enlargement or reduction, and (b) in the case of any waiver by Landlord of a specific obligation of an assignee or transferee of Tenant, such waiver shall also be deemed a waiver of such obligation with respect to Tenant named herein and the immediate and remote assignors or transferors of such assignee or transferee.
13.06 - Nothing in this Lease shall in any way restrict Landlord's right to assign or encumber this Lease in its sole and absolute discretion. Should the Landlord assign this Lease, or should Landlord encumber all or any portion of the Building or Project, and should the holder of such encumbrance succeed to the interest of Landlord, then, subject to the requirements and conditions of Section 14 below, Tenant shall be bound to said assignee or any such holder under all the terms, covenants and conditions of this Lease for the balance of the Lease term remaining after such succession and Tenant shall attorn to such succeeding party as its Landlord under this Lease promptly under any such succession. Tenant agrees that should any party so succeeding to the interest of Landlord require a separate agreement of attornment regarding the matters covered by this Lease, then, subject to the requirements and conditions of Section 14 below, Tenant shall enter into such attornment agreement, provided the same does not modify any of the provisions of this Lease and has no effect upon Tenant's continued occupancy of the Premises.
ARTICLE 14 LANDLORD'S RIGHT OF ACCESS
14.01 - Landlord may, at any time during Tenant's occupancy, during reasonable business hours, enter either to view the Premises or to show the same to others, or to facilitate repairs to the Building or premises, or to introduce, replace, repair, alter or make new or change existing connections from any fixtures, pipes, wires, ducts, conduits or other construction therein, or remove, without being held responsible therefor, placards, signs, lettering, window or door coverings and the like not expressly consented to by Landlord. Notwithstanding the foregoing, Landlord will make reasonable efforts to notify Tenant prior to such entry as to the fact of Landlord's intended entry and the reasons thereof. With regard to the exercise of its rights hereunder, Landlord shall utilize commercially reasonable efforts to minimize any disruption to Tenant's business at the Premises. Upon reasonable prior oral notification to Tenant, Landlord may, during the last ninety (90) days of the Term, enter the Premises free from hindrance or control of Tenant to show the Premises to prospective tenants at times which shall not unreasonably interfere with Tenant's business. If Tenant shall vacate the Premises during the last month of the Term, Landlord shall have the unrestricted right to enter the same after Tenant's moving to commence preparations for the succeeding tenant or for any other purpose whatsoever, without affecting Tenant's obligation to pay Rent for the full Term.
ARTICLE 15 TRANSFER OF TENANT
15.01 - Landlord hereby waives any right to transfer Tenant [INTENTIONALLY OMITTED]
ARTICLE 16 FIRE CLAUSE
16.01 - If the Premises are damaged by fire or other casualty, Landlord shall forthwith repair the same, subject to the provisions of this Article 16 hereinafter set forth, as soon as practicable, unless this Lease is terminated as provided below.
16.02 - If (i) the Premises are damaged to such an extent that repairs cannot, in Landlord's sole but reasonable judgment, be completed within one hundred eighty (180) days after the date of the casualty, or (ii) the Premises are damaged or destroyed as a result of a risk which is not insured by Landlord under any insurance policies maintained by Landlord, or (iii) the Premises are damaged or destroyed during the last six (6) months of the Term of this Lease, or (iv) the Building is damaged in whole or in part (whether or not the Premises are damaged) to such an extent that the same cannot, in Landlord's sole judgment, be operated economically as an integral unit, or (v) insurance proceeds for the restoration of the Premises or the Building are not available due to the election of Landlord's mortgagee or otherwise, or (vi) Landlord's mortgagee is in possession after a foreclosure and elects not to rebuild, then and in any such event, Landlord may at its option terminate this Lease by notice in writing to Tenant within ninety (90) days after the day of such occurrence. Unless Landlord elects to terminate this Lease as hereinabove provided, this Lease shall remain in full force and effect.
16.03 - If any fire or other casualty is not the result of the act, omission, negligence or willful misconduct of Tenant or Tenant's employees, contractors, licensees, or agents, then during the period the Premises are rendered unusable by such damage and/or the making of repairs Tenant shall be entitled to a reduction in Basic Rent in the proportion that the area of the Premises rendered unusable by such damage bears to the total area of the Premises. No damages, compensation, or claim shall be payable by Landlord for inconvenience, loss of business, or annoyance arising from any repair or restoration of any portion of the Premises or the Building. Subject to the provisions of Section 16.01, Landlord shall diligently proceed
9
to have such repairs made promptly.
16.04 - Landlord shall not be required to repair any injury or damage or to make any repairs or replacements of any improvements installed in the Premises by or for Tenant. If the cost of performing such repairs exceeds the actual proceeds of insurance paid or payable to Landlord on account of such casualty, or if Landlord's mortgagee or the lessor under a ground or underlying lease shall require that any insurance proceeds from a casualty loss be paid to it, Landlord may terminate this Lease unless Tenant, within fifteen (15) days after demand therefor, deposits with Landlord a sum of money sufficient to pay the difference between the cost of repair and the proceeds of the insurance available to Landlord for such purpose. Landlord shall not be obligated to repair, restore or replace any fixture, improvement, alteration, furniture or other property owned, installed or made by Tenant, all of which shall be repaired, restored or replaced by Tenant.
ARTICLE 17 CONDEMNATION
17.01 - If all or any part of the Premises, Building, or the Project shall be taken as a result of the exercise of the power of eminent domain or agreement in lieu thereof, this Lease shall terminate as to the part so taken as of the date of taking. In the case of a partial taking, either Landlord or Tenant shall have the right to terminate this Lease as to the balance of the Premises by giving written notice to the other within thirty (30) days after such date; provided, however, that a condition to the exercise by Tenant of such right to terminate shall be that a portion of the Premises must have been taken, and the portion so taken shall be of such extent and nature as substantially to handicap, impede or impair Tenant's use of the balance of the Premises. The forcible leasing by any competent authority of any portion of the Project other than the Premises shall have no effect upon this Lease. In case of any taking or condemnation, whether or not the Term shall cease and terminate, the entire award shall be the property of Landlord, and Tenant hereby assigns to Landlord all its right, title and interest in and to any such award. Tenant however, shall be entitled to claim, prove and receive in the condemnation proceeding such awards as may be allowed for fixtures and other equipment installed by it, but only if such awards shall be made by the court in addition to (and shall in no manner whatsoever reduce) the award made by it to Landlord for the land and improvements or part thereof so taken.
17.02 - In the event of a temporary taking or condemnation of all or any part of the Premises for any public or quasi-public use or purpose, this Lease shall be unaffected, and Tenant shall continue to pay in full Basic Rent and all Additional Rent payable for such period. In the event of any such temporary taking, notwithstanding the provisions of Section 17.01, Tenant shall be entitled to claim, prove and receive the portion of the award for such taking that represents compensation for use or occupancy of the Premises during the Term, and Landlord shall be entitled to appear, claim, prove and receive the portions of the award that represent the cost of restoration of the Premises and the use or occupancy of the Premises after the end of the Term.
ARTICLE 18 DEFAULTS AND REMEDIES
18.01 - It is hereby mutually agreed that: (a) if Tenant shall fail (i) to pay Rent or other sums which Tenant is obligated to pay by any provision of this Lease, when and as it is due and payable hereunder and without demand therefore, or (ii) to keep and perform each and every covenant, condition and agreement herein contained on the part of Tenant to be kept and performed; or (b) if the Premises are deserted, vacated, or not used regularly or consistently as would normally be expected for similar premises put to general office use, even though the Tenant continues to pay the stipulated monthly Basic Rent; or (c) if Tenant shall be taken by execution or other process of law; or (d) if Tenant shall (i) generally not pay Tenant's debts as such debts become due, (ii) become insolvent, (iii) make an assignment for the benefit of creditors, (iv) file, be the entity subject to, or acquiesce in a petition in any court (whether or not filed by or against Tenant pursuant to any statute of the United States or any state and whether or not for a trustee, custodian, receiver, agent, or other officer for Tenant or for all or any portion of Tenant's property) in any proceeding whether bankruptcy, reorganization, composition, extension, arrangement, insolvency proceedings, or otherwise; then an event of default by Tenant (a "Default") shall have occurred hereunder. Upon the occurrence of a Default by Tenant, Landlord shall have the option to do and perform any one or more of the following in addition to, and not in limitation of, any other remedy or right permitted it by law or in equity or by this Lease:
(a)Landlord, with or without terminating this Lease, may immediately or at any time thereafter reenter the Premises and correct or repair any condition which shall constitute a failure on Tenant's part to keep, observe, perform, satisfy, or abide by any term, condition, covenant, agreement, or obligation of this Lease or of the rules and regulations now in effect or hereafter adopted or of any notice given Tenant by Landlord pursuant to the terms of this Lease, and Tenant shall fully reimburse and compensate Landlord on demand;
10
(b)Landlord, with or without terminating this Lease, may immediately or at any time thereafter demand in writing that Tenant vacate the Premises and thereupon Tenant shall vacate the Premises and remove therefrom all property thereon belonging to or placed on the Premises by, at the direction of, or with consent of Tenant within ten (10) days of receipt by Tenant of such notice from Landlord, whereupon Landlord shall have the right to reenter and take possession of the Premises. Any such demand, reentry and taking possession of the Premises by Landlord shall not of itself constitute an acceptance by Landlord of a surrender of this Lease or of the Premises by Tenant and shall not of itself constitute a termination of this Lease by Landlord;
(c)Landlord, with or without terminating this Lease, may immediately or at any time thereafter reenter the Premises and remove therefrom Tenant and all property belonging to or placed on the Premises by, at the direction of, or with consent of Tenant. Any such reentry and removal by Landlord shall not of itself constitute an acceptance by Landlord of a surrender of this Lease or of the Premises by Tenant and shall not of itself constitute a termination of this Lease by Landlord;
(d)Landlord, with or without terminating this Lease, may immediately or at any time thereafter relet the Premises or any part thereof for such time or times, at such rental or rentals and upon such other terms and conditions as Landlord in its sole discretion may deem advisable, and Landlord may make any alterations or repairs to the Premises which it may deem necessary or proper to facilitate such reletting; and Tenant shall pay all costs of such reletting, including, but not limited to, the cost of any such alterations and repairs to the Premises, attorneys' fees, and brokerage commissions; and if this Lease shall not have been terminated, Tenant shall continue to pay all rent and all other charges due under this Lease up to and including the date of beginning of payment of rent by any subsequent tenant of part or all of the Premises, and thereafter, Tenant shall pay monthly during the remainder of the term of this Lease the differences, if any, between the rent and other charges collected from any such subsequent tenant or tenants and the rent and other charges reserved in this Lease, but Tenant shall not be entitled to receive any excess of any such rents collected over the rents reserved herein;
(e)Landlord may immediately or at any time thereafter terminate this Lease, and this Lease shall be deemed to have been terminated upon receipt by Tenant of written notice of such termination; upon such termination Landlord shall recover from Tenant all damages Landlord may suffer by reason of such termination, including, without limitation, unamortized sums expended by Landlord for construction of Tenant Improvements, all arrearage in rentals, costs, charges, additional rentals, and reimbursements, the cost (including court costs and attorneys' fees) of recovering possession of the Premises, the cost of any alteration of or repair to the Premise which is necessary or proper to prepare the same for reletting and, in addition thereto, Landlord at its election shall have and recover from Tenant either (1) an amount equal to the excess, if any, (discounted to present value using the discount rate of the Federal Reserve Bank of Atlanta at the time of award plus one percent (1%)) of the total amount of all rents and other charges to be paid by Tenant for the remainder of the term of this Lease over the then reasonable rental value of the Premises for the remainder of the term of this Lease, or (2) the rents and other charges which Landlord would be entitled to receive from Tenant pursuant to the provisions of subparagraph (d) above of this Section 18.01 if the Lease were not terminated. Such election shall be made by Landlord by serving written notice to Tenant of its choice of one of the two alternatives within thirty (30) days of the notice of termination.
18.02 - If Landlord reenters the Premises or terminates this Lease pursuant to any of the provisions of this Lease, Tenant hereby waives all claims for damages which may be caused by such reentry or termination by Landlord. Tenant shall and does hereby indemnify and hold Landlord harmless from any loss, costs (including court costs and attorneys' fees), or damages suffered by Landlord by reason of such reentry or termination. No such reentry or termination shall be considered or construed to be a forcible entry.
18.03 - Each right and remedy of Landlord provided for in this Lease or now or hereafter existing at law or in equity or by statute or otherwise shall be cumulative and concurrent and shall be in addition to every other right or remedy provided for in this Lease now or hereafter existing at law or in equity or by statute or otherwise. The exercise or commencement by Landlord of any one or more the rights or remedies provided for in this Lease now or hereafter existing at law or in equity or by statute or otherwise shall not preclude the later exercise by Landlord of any or all of such other rights or remedies.
18.04 - No waiver by Landlord of any breach by Tenant of any of the terms, provisions and covenants contained herein shall be deemed or construed to constitute a waiver of any other or subsequent breach by Tenant of any of the terms, provisions and covenants contained herein. Landlord's acceptance of the payment of rent (or portions thereof) or any other payments hereunder after the occurrence of and during the continuance of an Event of Default (or with knowledge of a breach of any term or provision of this Lease, which with the giving of notice and the passage of time, or both, would constitute an Event of Default) shall not be construed as a waiver of such default. Forbearance by Landlord to enforce one or more of the remedies herein provided upon the occurrence of an Event of Default shall not be deemed or construed to constitute a waiver of such default. No act or omission by Landlord or its agents during the
11
Lease Term shall be deemed an acceptance of the surrender of the Premises and no agreement to accept a surrender of the Premises shall be valid unless in writing and signed by Landlord. No surrender of the Premises or any part hereof by delivery of keys or otherwise shall operate to terminate this Lease unless and until expressly accepted in writing by Landlord. Landlord shall not be required to relet the Premises nor exercise any other right granted to Landlord hereunder nor shall Landlord be under any obligation to minimize or mitigate Tenant's loss or damage as a result of the default of Tenant under this Lease.
18.05 - If this Lease is terminated pursuant to this Section, Landlord may relet the Premises or any part thereof, alone or together with other premises, for such term or terms (which may be greater or less than the period which otherwise would have constituted the balance of the Term) and on such terms and conditions (which may include concessions or free rent and alterations of the Premises) as Landlord, in its absolute discretion, may determine, but Landlord shall not be liable for, nor shall Tenant's obligations hereunder by diminished by reason of, any failure by Landlord to relet the Premises or any failure by Landlord to collect any rent due upon such re letting.
18.06 - The provisions of this Article 18 are subject to the Bankruptcy Laws of the United States of America and the State of Georgia which may, in certain cases, limit the rights of Landlord to enforce some of the provisions of this Article in proceedings thereunder. To the extent that limitations exist by virtue thereof, the remaining provisions hereof shall not be affected thereby but shall remain in full force and effect. The provisions of this Article 19 shall be interpreted in a manner which results in a termination of this Lease in each and every instance, and to the fullest extent and at the earliest moment that such termination is permitted under the federal and state bankruptcy laws, it being of prime importance to Landlord to deal only with tenants who have, and continue to have, a strong degree of financial strength and financial stability.
18.07 - All rents received by Landlord in any reletting after Tenant's default shall be applied, first to the payment of such expenses as Landlord may have incurred in recovering possession of the Premises and in reletting the same (including brokerage fees), second to the payment of any costs and expenses incurred by Landlord, either for making the necessary repairs (including fitting up the space for such reletting) to the Premises or in curing any default on the part of Tenant of any covenant or condition herein made binding upon Tenant. Any remaining rent shall then be applied toward the payment of Rent due from Tenant, together with interest and penalties as defined in Section 3.04, and Tenant expressly agrees to pay any deficiency then remaining. Landlord shall in no event be liable in any way whatsoever (nor shall Tenant be entitled to any set off) for Landlord's failure to relet the Premises, and Landlord, at its option, may refrain from terminating Tenant's right of possession, and in such case may enforce against Tenant the provisions of this Lease for the full Term.
ARTICLE 19 SUBORDINATION CLAUSE
19.01 - This Lease shall be subject and subordinate at all times to the lien of any mortgage or deed of trust or other encumbrance(s) which may now or which may at any time hereafter be made upon the Building of which the Premises is a part of any portion thereof, or upon Landlord's interest therein. This clause shall be selfoperative, and no further instrument of subordination shall be required to effect the subordination of this Lease. Nonetheless, in confirmation of such subordination, Tenant shall execute and deliver such further instruments(s) subordinating this Lease to the lien of any such mortgage or deed of trust or any other encumbrance(s) as shall be desired by any mortgages or party secured or proposed to be secured thereby, and Tenant hereby appoints Landlord the attorney-in-fact of Tenant, irrevocably, to execute and deliver any such instrument(s) for Tenant. If the interest of Landlord under this Lease shall be transferred by reason of foreclosure or other proceedings for enforcement of any mortgage or deed of trust on the Premises or Building, Tenant shall be bound to the transferee at the option of the transferee, under the terms, covenants and conditions of this Lease for the remaining Term, including any extensions or renewals, with the same force and effect as if the transferee were Landlord under this Lease, and, if requested by such transferee, Tenant agrees to attorn to the transferee as its Landlord. The holder of any mortgage or deed of trust encumbering the Project shall have the right, unilaterally, at any time to subordinate fully or partially its mortgage or deed of trust or other security instrument to this Lease on such terms and subject to such conditions as such holder may consider appropriate in its discretion. Upon request Tenant shall execute and deliver an instrument confirming any such full or partial subordination.
ARTICLE 20 SURRENDER OF POSSESSION
20.01 - Upon the expiration or earlier termination of the Term, Tenant shall surrender the Premises and all keys and locks connected therewith to Landlord in good order and repair (ordinary wear and tear excepted). Subject to the provisions of Article 11, any and all improvements, repairs, alterations and all other property attached to, used in connection with or otherwise installed upon the Premises (i), shall, immediately upon the completion of the installation thereof, be and become Landlord's property without payment therefor by Landlord, and (ii) shall be surrendered to Landlord upon the expiration or earlier termination of the Term, except that any machinery, equipment or fixtures installed by Tenant and used
12
in the conduct of the Tenant's trade or business (rather than to service the Premises or any of the remainder of the Building or the Project generally) and all other personality of Tenant shall remain Tenant's property and shall be removed by Tenant upon the expiration or earlier termination of the Term, and Tenant shall promptly thereafter fully restore any of the Premises or the Building damaged by such installation or removal thereof. Such property of Tenant which it fails to remove either from the Premises or the Building after the termination of this Lease shall be considered as abandoned by Tenant and may be disposed of by Landlord in any manner whatsoever without accounting to Tenant for same or being liable in any way to Tenant for such disposition, but Tenant shall, upon demand, reimburse Landlord for the cost of such disposal.
ARTICLE 21 TENANT HOLDING OVER
21.01 - If Tenant or any person claiming by, through or under Tenant shall not immediately surrender possession of the Premises at the expiration or earlier termination of the Term, and if Landlord elects, in its sole discretion, to permit Tenant to hold over, then Landlord shall be entitled to recover compensation for such use and occupancy at a per diem rate equal to one hundred and fifty percent (150%) of the Basic Rent and Additional Rent payable hereunder for the month just prior to the expiration or earlier termination of the Term, unless the parties have agreed otherwise in writing to a different rate. In the event of any such hold over without Landlord's consent or approval Landlord shall also continue to be entitled to retake or recover possession of the Premises as herein before provided in case of Default on the part of Tenant, and Tenant shall be liable to Landlord for any loss or damage it may sustain by reason of Tenant's failure to surrender possession of the Premises immediately upon the expiration or earlier termination of the Term. Any hold over by Tenant with Landlord's express consent or approval shall be deemed to constitute a month-to-month tenancy terminable by either party on thirty (30) days prior written notice to the other, unless Landlord notifies Tenant of a specific date by which Tenant must vacate the Premises. In such event such hold over shall be for a period of time beginning on the day next following the last day of the expiring Term and ending on such hold over period termination date as specified by Landlord in writing. Tenant hereby agrees that all the obligations of Tenant and rights of Landlord applicable during the Term shall be equally applicable during such period of holdover occupancy, subject to this Section 21.01.
ARTICLE 22 ESTOPPELS
22.01 - Tenant shall, without charge thereof, at any time and from time to time, with five (5) days after request by Landlord, execute, acknowledge and deliver to Landlord a written estoppel certificate certifying to Landlord, any mortgagee, assignee of a mortgage, or any purchaser of the Project, or any other person designated by Landlord, as of the date of such estoppel certificate: (a) that Tenant is in possession of the Premises; (b) that this Lease is unmodified and in full force and effect (or if there have been modifications, that this Lease is in full force and effect as modified and setting forth such modification); (c) whether or not there are then existing any set offs or defenses against the enforcement of any right or remedy of Landlord, or any duty or obligation of Tenant hereunder (and, if so, specifying the same in detail); (d) the amount of the Basic Rent and the dates through which Basic Rent and Additional Rent have been paid; (e) that Tenant has no knowledge of any then uncured defaults on the part of Landlord under this Lease (or if Tenant has knowledge of any such uncured defaults, specifying the same in detail); (f) that Tenant has no knowledge of any event having occurred that authorizes the termination of this Lease by Tenant (or if Tenant has such knowledge, specifying the same in detail); (g) the amount of any Security Deposit held by Landlord; and (h) such reasonable other information requested by Landlord, such mortgagee, assignee of such mortgagee, such purchaser or such other person. Failure to deliver the certificate within five (5) days after request by Landlord, then by such failure Tenant shall irrevocably constitute and appoint Landlord as its attorney-in-fact to execute and deliver the certificate to any third party.
ARTICLE 23 NOTICE AND DEMANDS
23.01 - All notices required or permitted hereunder shall be deemed to have been given if mailed in any United States Post Office by certified or registered mail, postage prepaid, return receipt requested, addressed to Landlord or Tenant respectively, at the following addresses or to such other addresses as the parties hereto may designate to the other in writing from time to time;
AS TO LANDLORD:
Georgia Motor Trucking Association, Inc.
2060 Franklin Way
Suite 200
Marietta, GA 30067
13
AS TO TENANT:
Revo Squared, LLC
2060 Franklin Way
Suite 100
Marietta, GA 30067
23.01 - Tenant hereby elects domicile at the Premises for the purpose of service of all notices, writs of summons, or other legal documents or process, in any suit, action or proceeding which Landlord may undertake under this Lease.
ARTICLE 24 MISCELLANEOUS
24.01 - The term "Tenant" shall include legal representatives, successors and permitted assigns. All covenants herein made binding upon Tenant shall be construed to be equally applicable to and binding upon its agents, employees and others claiming the right to be in the Premises or in the Building through or under Tenant. If more than one individual, firm, or corporation shall join as Tenant, singular context shall be construed to be plural wherever necessary and the covenants of Tenant shall be the joint and several obligations of each party signing as Tenant and when the parties signing as Tenant are partners, shall be the obligation of the firm and of the individual members thereof.
24.02 - Feminine or neuter pronouns shall be substituted for those of the masculine form and the plural shall be substituted for the singular, wherever the context shall require. It is also agreed that no specific words, phrases or clauses herein used shall be taken or construed to control, limit or cut down the scope or meaning of any general words, phrases or clauses used in connection therewith.
24.03 - Notwithstanding anything to the contrary contained in this Lease, Tenant shall look only to Landlord's ownership interest in the Project for satisfaction of Tenant's remedies for the collection of a judgment (or other judicial process) requiring the payment of money by Landlord in the event of any default by Landlord hereunder, and no other property or assets of the partners or principals of Landlord, disclosed or undisclosed, shall be subject to levy, execution or the enforcement procedure for the satisfaction of Tenant's remedies under or with respect to this Lease, the relationship of Landlord and Tenant hereunder or Tenant's use or occupancy of the Premises. No personal liability or personal responsibility is assumed by, nor shall at any time be asserted or enforceable against Landlord, its partners or its principals, or their respective heirs, legal representatives, successors and assigns on account of this Lease or any covenant, undertaking, or agreement of Landlord contained herein. If any provision of this Lease either expressed or implied obligates Landlord not to unreasonably withhold its consent or approval, an action for declaratory judgment or specific performance shall be Tenant's sole right and remedy in any dispute as to whether Landlord has breached such obligation.
24.04 - Tenant and Landlord expressly agree that the space is designed for general office use and that there shall be no implied warranties of merchantability, habitability, or fitness for any other purpose arising out of this Lease, and there are no warranties which extend beyond those expressly set forth in this Lease
24.05 - This Lease shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, personal representatives, successors and assigns. This provision shall not be deemed to grant Tenant any right to assign this Lease or sublet the Premises or any part thereof other than as provided in Article 13 hereof.
24.06 - It is understood and agreed by and between the parties hereto that this Lease contains the final and entire agreement between said patties, and that they shall not be bound by any terms, statements, conditions or representations, oral or written, express or implied, not herein contained. This Lease may not be modified orally or in any manner other than by written agreement signed by the parties hereto.
24.07 - Every agreement contained in this Lease is, and shall be construed as a separate and independent agreement. If any term of this Lease or the application thereof to any person or circumstances shall be invalid and unenforceable, the remaining provisions of this Lease, the application of such term to persons or circumstances other than those as to which it is invalid or unenforceable, shall not be affected.
24.08 - Whenever a period of time is herein prescribed for action to be taken by Landlord, Landlord shall not be liable or responsible for, and there shall be excluded from the computation for any such period of time, any delays due to strikes, riots, acts of God, shortages of labor or materials, war, governmental laws, regulations or restrictions, or any other cause of any kind whatsoever which is beyond the reasonable control of Landlord.
24.09 - The submission of this Lease to Tenant shall not be construed as an offer nor shall Tenant have any rights with respect thereto unless Landlord executes a copy of this Lease and delivers it to Tenant.
14
24.10 - If, in connection with obtaining financing for the Project (including syndication or sale/leaseback), any lender or ground Landlord shall request modifications to this Lease as a condition for such financing, Tenant will not unreasonably withhold, delay, or defer its consent thereto, provided that such modifications do not increase the monetary obligations of Tenant hereunder or materially adversely affect Tenant's use and enjoyment of the Premises.
24.11 - Time shall be of the essence with respect to all of Tenant's obligations under this Lease.
24.12 - This Lease shall create the relationship of landlord and tenant between Landlord and Tenant; no estate shall pass out of Landlord, and Tenant has only a usufruct which is not subject to levy and sale
24.13 - Tenant represents and warrants that it has not entered into any agreement with, nor otherwise had any dealings with, any broker or agent except for ICON Commercial Interests in connection with the negotiation or execution of this Lease which could form the basis of any claim for a brokerage fee, commission, finder's fee, or any other compensation in connection herewith, and Tenant shall indemnify, defend and hold Landlord harmless from any costs (including, but not limited to, court costs and attorneys' fees), or liability for commissions by any broker or agent other than hereinabove listed with respect to this Lease which arises out of any agreement or dealings, or alleged agreement or dealings, between Tenant and any such agent or broker. Landlord agrees to pay a commission to the agent or broker herein listed in accordance with a separate agreement.
24.14 - Landlord covenants and agrees that upon Tenant paying the Rent and any other charges due and payable and by observing and performing all the terms, covenants and conditions, on Tenant's part to be observed and performed, Tenant may peaceably and quietly enjoy the Premises hereby demised, subject, nevertheless, to the terms and conditions of this Lease and to any mortgages and deeds of trust herein before mentioned.
24.15 - Landlord and Tenant each agree to and they hereby do waive trial by jury in any action, proceeding or counterclaim brought by either of the parties hereto against the other on any matters whatsoever arising out of or in any way connected with this Lease the relationship of Landlord and Tenant, Tenant's use or occupancy of the Premises and/or any claim of injury or damage, and any statutory remedy.
24.16 - This Lease shall be construed and governed by the laws of the state of Georgia. Should any provision of this Lease and/or its conditions be illegal or unenforceable under the laws of the state, it or they shall be considered severable, and the Lease and its conditions shall remain in force and be binding upon the parties hereto as though the said provision had never been included.
24.17 - The individual(s) executing this Agreement on behalf of Tenant hereby represents and warrants that such individual(s) has proper authority to sign and enter into this Lease Agreement on behalf of Tenant, and that Tenant is properly constituted and registered in the State of Georgia and Secretary of State's office. Should such individual(s) lack such authority, then such individual(s) shall be personally liable and responsible for all of such entity's obligations arising under the Lease Agreement.
24.18 - Exhibit A "Floor Plan", Exhibit A-1 "Contraction Premises", Exhibit B "Schedule of Improvements", Exhibit C "Rules and Regulations", Exhibit D "Special Stipulations", and Exhibit E ("Commencement Date Agreement").
15
IN WITNESS WHEREOF, Landlord has hereunto set its hand and seal, or has caused its name to be hereunto subscribed and Tenant has hereunto set its hand and seal, or has caused its corporate name to be hereunto subscribed and its corporate seal to be hereunto affixed and attested by its duly authorized officers, as the case may be, as of the day and year first above written.
LANDLORD:
Georgia Motor Trucking Association, Inc.
a Georgia not-for-profit corporation
Witness/Attest: By: /s/ Ed Crowell
Ed Crowell
Title: President and CEO
[ SEAL ]
TENANT:
Revo Squared, LLC
a Georgia limited liability company
Witness/Attest: /s/ [illegible] By: /s/ W.E. Campbell
Name: William Campbell
Title: CEO
[ SEAL ]
16
EXHBITA
FLOOR PLAN
17
EXHIBIT A-1
CONTRACTION PREMISES
18
EXHIBIT B
SCHEDULE OF IMPROVEMENTS
Landlord, at Landlord's sole expense, shall perform the following leasehold improvements to the Premises
Paint.
● | All walls two coats latex flat paint with color selected by Tenant. |
● | All door frames two coats semi-gloss enamel with color selected by Tenant. |
Ceiling.
● | Replace all stained/damaged ceiling tile and insure uniform look. |
Carpet.
● | Professionally shampoo and/or steam clean carpeting throughout. |
Vinyl Composition tile.
● | Strip and re-wax break room and restroom. |
Tenant shall be responsible for cost and installation of 220v dedicated outlet (if needed).
Provide building standard signage on exterior monument sign directory strip and interior lobby panel and five (5) suite entrance keys.
19
EXHIBIT C
RULES AND REGULATIONS
1.The common area sidewalks, passages, and stairways shall not be obstructed by Tenant or used by Tenant for any purpose other than ingress and egress from and to their respective offices. The halls, passages, entrances, stairways, and roof are not for the use of the general public; and Landlord shall in all cases retain the right to control and prevent access thereto of all persons whose presence in the judgment of Landlord or its employees shall be prejudicial to the safety, character, reputation and interest of the Building and its Tenants.
2.The floors, skylights, windows, doors and transoms that reflect or admit light in passageways, or into any place in the Building, shall not be covered or obstructed by any Tenant.
3.No sign, advertisement or notice shall be inscribed, painted or affixed on any part of the outside or inside of said building unless first obtaining Landlord's prior written consent.
4.No additional locks shall be placed upon any doors of the Premises and Tenant shall not permit any duplicated keys to be made by any vendor other than through the Landlord. But if more than two (2) keys for any door or lock shall be desired, the additional number must be obtained from Landlord and be paid for by Tenant. Each Tenant must, upon the termination of its lease, leave the windows and doors in the demised Premises in like condition as the date of said Lease, and must then surrender all keys to the Premises.
5.No Tenant shall cause unnecessary labor by reason of carelessness and indifference to the preservation of good order and cleanliness in its premises or within the Building.
6.No Tenant shall do or permit anything to be done in said Premises, or bring or keep anything therein, which will in any way increase the rate of fire insurance on said Building or on Project kept therein or obstruct or interfere with the rights of other Tenants, or in any other way injure or annoy them or conflict with the laws relating to fires, or with the regulations of the Fire Department or with any insurance policy upon said Building or any part thereof, or conflict with any of the rules and ordinances of the Board of Health.
7.Each Tenant shall promptly and at its expense execute and comply with all laws, rules, orders, ordinances and regulations of the city, county, state or federal government, and of any department or bureau of any of them and of any other governmental authority having jurisdiction over the said Premises affecting Tenant's occupancy of the demised Premises or Tenant's business conducted thereon.
8.Nothing shall be thrown or allowed to drop by the Tenants, their clerks or employees out of the windows or doors or down the passages of the Building; and no Tenant shall sweep or throw or permit to be swept or thrown from the Premises, any dirt or other substance into any exterior corridors, halls, or stairways of said Building.
9.If Tenant desires to introduce signaling, telegraphic, telephonic or other wires and instruments into the Premises, Landlord will direct the electricians as to where and how the same are to be placed, and without such directions, no placing, boring or cutting for wires will be permitted. Landlord shall in all cases retain the right to require the placing and using of electrical-protecting devices to prevent the transmission of excessive currents of electricity into or through the Building, and to require the changing of wires and of their placing and arrangements as Landlord may deem necessary; and further to require compliance on the part of all using or seeking access to such wires with such rules as Landlord may establish relating thereto; and in the event of a non-compliance with such requirements and rules Landlord shall have the right to immediately cut and prevent the use of such wires.
10.Tenant shall not use or keep in the Building any explosives, kerosene, gasoline, benzene, camphene, burning fluid or other flammable material.
11.No Tenant, or employees of any Tenant, shall go upon the roof of the Building without written consent of Landlord.
12.Access may be had by Tenants to the halls, corridors and stairways in the Building and to the offices leased by them at any time or times. Access to the Building may be refused unless the person seeking admission is known to the watchman in charge or has a pass or is properly identified. The Landlord shall in no case be liable in damages for the admission or exclusion of any person from said Building. In case of invasion, mob riot, public excitement or other commotion, Landlord reserves the right to prevent access to the Building during continuance of the same by closing the doors or otherwise for the safety of the Tenants and protection of property in said Building.
20
13.Landlord in all cases shall, prescribe the method and manner in which any merchandise, heavy furniture, large packages or safes shall be brought in or taken out of the Building and also the hours at which such moving shall be done. Landlord shall in all cases retain the right to prescribe the weight and proper position of such heavy furniture and safes; and all damage done to the Building taking in or out such merchandise, heavy furniture, large packages or safes, or any damage done to the Building while said property shall be therein, shall be made good and paid for by Tenant by, through or under whom said damage may have been done. All furniture, safes or fixtures shall be provided with supports, glides or castors that will meet the approval of the Management of the Building.
Smoking is strictly prohibited within the Premises and Building.
14.Plumbing fixtures and appliances shall be used only for the purposes for which designed, and no sweepings, rubbish, rags or other unsuitable material shall be thrown or placed therein. Tenant shall pay damage resulting from misuse by a Tenant to any fixtures or appliances, and Landlord shall not in any case be responsible therefrom.
15.Tenant will refer all contractors, contractors' representatives and installation technicians rendering any service to them to Landlord for Landlord's supervision, approval and control before the performance of any contractual services. This provision shall apply to all work performed in the Building, including, but not limited to, installations of telephones, telegraph equipment, electrical devices and attachments, and any and all installations of every nature affecting floors, walls, woodwork, trim, windows, ceilings, equipment and any other physical portion of the Building.
16.Landlord reserves the right to rescind any of these rules and to make such other and further rules and regulations as in Landlord's judgment may from time to time be needed for the safety, care, maintenance, operation and cleanliness of the Building and for the preservation of good order therein, which, when so made and notice thereof shall have been given to the Tenant, shall have the same force and effect as if originally made a part of the foregoing Lease; and such other and further rules shall not, by Tenant under the foregoing Lease of the Premises therein referred to.
17.All normal trash and waste (i.e., waste that does not require special handling pursuant to the following sentence shall be disposed of through the janitorial service. Tenant shall not bring any hazardous waste or substances (as defined by CERCLA, RCRA or any other applicable governmental authority) into the Premises. Tenant hereby indemnifies and holds harmless Landlord, its successors and assigns (including the holders of any deeds to secure debt, mortgages or other security interest encumbering the Building or Project) from and against any loss, claims, demands, damage or injury Landlord may suffer or sustain as a result of Tenant's failure to comply with the provisions herein set forth.
21
EXHIBIT D
SPECIAL STIPULATIONS
A.Parking. The Building provides a parking ratio of four (4) spaces per every 1,000 rentable square feet of leased space at no cost to Tenant. Landlord agrees not to materially reduce the ratio of parking spaces to rentable square footage provided. All parking for the Building shall be open and unassigned on a "first come, first served" basis. Without diminishing Tenant's rights hereunder, Landlord has sole discretion to designate, at any future date, visitor parking spaces "Visitor Parking Only" close to the Building entrance (which shall be non-exclusive). Additionally, Landlord may, at any future date, designate one (1) handicap-width space "For Deliveries Only" (also non-exclusive).
B.Contraction Option. Tenant shall be granted the right to reduce the leased premises to 2,650 rentable square feet ("Reduced Premises" as depicted on Exhibit A-1) at any time from and after expiration of the twenty-fourth (24th) month of paid rent (scheduled to be January 1, 2020), subject to the following terms and conditions:
a. | Tenant provides Landlord with not less than three (3) months written notice of its election to reduce the premises. |
b. | Tenant agrees to pay the scope of all construction costs associated with the Reduced Premises (as depicted on Exhibit A-1) to include keyless electronic locksets and spec breakroom fixtures shown (building standard stainless sink and plastic laminate upper and lower cabinets. |
c. | At the time Tenant elects to reduce its premises, no Event of Default exists which remains uncured. |
d. | With respect to Article 5 ("Property Tax Increases"), Tenant's Share shall adjust to 13.42%. |
e. | The Effective Date for the Reduced Premises shall be three (3) months following notice. The Basic Rental Rate per square foot shall remain unchanged, but the new rent schedule shall be memorialized under a lease amendment. |
f. | Tenant agrees to grant Landlord possession at any time after providing notice to perform construction, with the leasehold interest in the vacated portion (1,976 rsf) unconditionally relinquished. |
g. | Tenant shall fund the construction costs within fifteen (15) days following completion and receipt of invoice. |
Upon execution hereof, Tenant shall submit separate checks as follows:
o | Security Deposit as set forth in Article 3.06 ($6,500.00) |
o | Advanced rent in the amount of $3,469.50 (constitute pre-payment of first month's rent). |
STATE OF GEORGIACOBB COUNTY
FIRST AMENDMENT TO LEASE AGREEMENT
THIS FIRST AMENDMENT TO LEASE AGREEMENT (hereinafter “First Amendment”), is made this 9th day of November 2021, by and between Georgia Motor Trucking Association, Inc., a Georgia not-forprofit corporation (hereinafter "Landlord"), and Revo Squared, LLC, a Georgia limited liability company (hereinafter "Tenant").
WITNESSETH:
WHEREAS, Landlord and Tenant entered into that certain Lease Agreement (the "Original Lease"), dated as of October 9, 2018, for the premises consisting of approximately 4,626 rentable square feet (Suite 100) in that certain building known located at 2060 Franklin Way, Marietta, GA 30067 ("the Building"), and
WHEREAS, Landlord and Tenant desire to modify and amend certain terms and conditions of the Lease, in the manner and for the purposes herein set forth.
NOW THEREFORE, for and in consideration of the mutual covenants contained herein, and for Ten and No Dollars ($10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereby covenant and agree as follows:
1. | Term. The term of the lease shall not be extended. |
2. | Premises. The premises shall be reduced to 2,086 rentable square feet ("Reduced Premises") as set forth in Exhibit A attached. The common area factor is hereby modified to 1.12%. |
3. | The suite number shall be known as Suite 100: |
4. | Rent. Basic Rent as set forth in Article 3.02 shall modify and be effective as of December 1, 2021 as follows: |
Period | Annual Rate/S.F. | Annual Basic Rent | Monthly Basic Rent |
12/01/21 – 11/30/22 | $18.31 | $38,184.00 | $3,182.00 |
12/01/22 – 12/31/23 | $18.77 | $42,412.50 (13 mos.) | $3,262.50 |
5. | Past Due Rent. During the pandemic commencing March 2020, Landlord electively deferred a portion of the Basic Rent in the amount of $13,585.00 (hereinafter "Deferred Rent"). Tenant acknowledged Landlord presented an amendment in March 2020 with a revised rent schedule, which provided that the Deferred Rent would be satisfied by 12/31/2020, but that such amendment was never returned executed by Tenant. Tenant hereby acknowledges that, in addition to the Deferred Rent, there has accrued an additional $8,151.00 of Basic Rent past due, such that the total Basic Rent past due is $21,736.00. Upon execution hereof, Tenant shall pay to Landlord $4,986.00 of Past Due Rent, and Landlord shall, in turn, accept the balance of $16,750.00, without penalties or interest, in twenty-five (25) monthly payments as follows: |
12/01/21 - 12/31/23 Twenty-five (25) equal monthly payments of $670.00
6. | Improvements. Tenant shall solely bear the expense for demising the Premises per Exhibit 'A' attached (the "Work") and shall have such work performed in a workmanlike manner by licensed and commercial-grade contractor(s) utilizing materials matching building standards and in in compliance with all applicable codes as set forth in Article 9 of the Lease. A COI and lien waivers from all contractors performing the Work shall be required. Landlord shall review and inspect the Work within five (5) days from completion and inform Tenant if such Work is complete and satisfactory. Tenant agrees to diligently pursue any punch list items identified by Landlord. |
7. | No Other Modifications. Except as expressly modified by this First Amendment, the Lease remains unmodified and in full force and effect. |
8. | Transfers, Successors and Assigns. This First Amendment shall inure to the benefit of and shall be binding upon Landlord, Tenant, and their respective transfers, successors and assigns. |
9. | Time of Essence. Time is of the essence of this First Amendment. |
10. | Georgia Law. This First Amendment shall be construed and interpreted under the laws of the State of Georgia. |
By Execution of this Agreement, Tenant acknowledges and agrees to the following:
a) | Landlord has fulfilled all of its duties and responsibilities under the Lease Agreement. |
b) | The Lease Agreement is in full force and effect and has not been revised, modified or altered except as specifically set forth in this First Amendment. |
c) | Tenant has no claims against Landlord, or its agent or representatives, including, but not limited to, any claims to offset or waive rents. |
d) | Landlord has not made any representation to or with Tenant concerning the Lease Agreement or the leased Premises that is not contained in the Lease Agreement or this First Amendment. |
[SIGNATURES ON PAGE TO FOLLOW]
IN WITNESS WHEREOF, the undersigned have caused this First Amendment to be executed under seal and delivered, on the date and year first above written.
LANDLORD:
Georgia Motor Trucking Association, Inc.
a Georgia not-for-profit corporation
Witness: /s/ [illegible] By: /s/ Curt Earnest
Name: Curt Earnest
Title: CSO
Date: 11-9-21
TENANT:
Revo Squared, LLC
a Georgia limited liability company
Witness: /s/ [illegible] By: W.E. Campbell
Name: William E. Campbell
Title: CEO
Date: 11-9-21
EXHIBIT A
FLOOR PLAN
~ Approx. 2086 RSF
ASSIGNMENT OF LEASES
(2060 Franklin Way)
THIS ASSIGNMENT OF LEASES is made and entered into as of the 15th day of December, 2021, by and between Georgia Motor Trucking Association, Inc., a Georgia corporation (hereinafter called "Seller") and Lebow 1031 Legacy, LLC, a Georgia limited liability company (hereinafter called "Purchaser").
WITNESSETH:
WHEREAS, Seller has contemporaneously with the execution hereof sold and conveyed to Purchaser all that tract or parcel of land lying and being in Land Lots 712 and 713 of the 17th District of Cobb County, Georgia, commonly known as 2060 Franklin Way, Marietta, Georgia, together with improvements located thereon (hereinafter collectively referred to as the "Property");
WHEREAS, in connection with the sale and conveyance of the Property, Seller and Purchaser intend that Seller shall transfer and assign Seller's interest in and to all tenant leases demising space in the Property and that Purchaser shall assume all Seller's obligations under all such leases arising from and after the date hereof.
NOW, THEREFORE, for and in consideration of the mutual promises contained herein and of other good and valuable consideration, the receipt, adequacy and sufficiency whereof are hereby acknowledged, Seller and Purchaser hereby agree as follows:
1.Seller does hereby sell, assign, convey and set over absolutely unto Purchaser all of the leases, occupancy agreements, tenancies, usufructs and subleases relating to the Property (hereinafter collectively called the "Leases") which are set forth in Exhibit "A", attached hereto and made a part hereof; together with any and all guarantees of any of the Leases; together with any other occupancy arrangements concerning the Property; together with any and all security, escrow, damage, or other deposits made by tenants, occupants or lessees, now held by Seller with respect to the Leases or which are refundable under the terms of any lease; and together with all records (hereinafter collectively called the "Records") relating to the Leases (including, without limitation, move-in and move-out reports and other records relating to security deposits). Simultaneously herewith Seller is delivering to Purchaser the originals or true and complete copies of all Leases and Records.
2.Purchaser accepts the aforesaid assignment subject to the rights of lessees which first accrue on and after the date hereof, and not before. Purchaser assumes and agrees to be bound by and timely perform, observe, discharge, and otherwise comply with each and every one of the agreements, duties, obligations, covenants and undertakings upon the lessor's part to be kept and performed under the Leases, but only to the same extent as same would have arisen and been binding on the Seller commencing from and after the date hereof, said agreement being solely for the benefit of Seller and not for the benefit of any third party.
3.Seller indemnifies and agrees to hold harmless Purchaser from and against any and all liabilities, claims, demands, obligations, assessments, losses, costs, damages and expenses of any nature whatsoever (including, but without limiting the generality of the foregoing, attorneys' fees and court costs) which Purchaser may incur, sustain or suffer or which may be charged against Purchaser, arising out of, pertaining to or in any way connected with Seller's obligations, duties and liabilities under the Leases, or any of them, prior to the date hereof.
4.Purchaser indemnifies and agrees to hold harmless Seller from and against any and all liabilities, claims, demands, obligations, assessments, losses, costs, damages and expenses of any nature whatsoever (including, but without limiting the generality of the foregoing, attorneys' fees and court costs) which Seller may incur, sustain or suffer, or which may be asserted or assessed against Seller on or after the date hereof, arising out of, pertaining to or in any way connected with the obligations, duties and liabilities under the Leases, or any of them, arising from and after the date hereof.
5.Seller warrants to Purchaser that Seller is the sole owner and holder of the landlord's interest under the Leases, that there are no assignments of the landlord's interest in the Leases outstanding as of the date of this Agreement, and that none of the property or interests assigned hereby is subject to any liens, security interests or other encumbrances. Seller warrants to Purchaser that set forth on Exhibit "A" are all of the leases, tenancies, usufructs and other occupancy arrangements presently existing at the Property, that none of the Leases has been amended, renewed or extended except as set forth on Exhibit "A", that each lease delivered to Assignee is the full agreement concerning the terms of each tenant's tenancy, and that there are no rental, lease or other commissions now or hereafter payable to any person or entity with respect to the Leases or any extension or renewal thereof.
6.The burden of the indemnities made in Paragraphs 3 and 4 hereof shall not be assigned by the indemnifying party thereunder. Except as aforesaid, this Agreement shall bind and inure to the benefit of the parties and their respective successors, legal representatives and assigns.
7.Neither this Agreement nor any term, provision or condition hereof may be changed, amended or modified, and no obligation, duty or liability of any party hereto may be released, discharged or waived, except in a writing signed by all parties hereto. This Agreement contains the entire understanding of the parties with regard to the subject matter hereof.
IN WITNESS WHEREOF, Seller and Purchaser have caused this Agreement to be executed under seal as of the date first above written.
SELLER:
Georgia Motor Trucking Association, Inc.
a Georgia corporation
By: /s/ Edward Crowell
Edward Crowell, President
[ CORPORATE SEAL ]
PURCHASER:
Lebow 1031 Legacy, LLC,
a Georgia limited liability company
By: /s/ Eric Ranney
Eric D. Ranney, Member
Exhibit "A"
1.Agreement of Lease dated January 5, 2011 between Georgia Motor Trucking Association, Inc. and ServiceMaster Downtown Commercial, as amended by Commencement Date Agreement dated January 5, 2011, and by First Amendment to Lease Agreement dated April , 2017.
2.Agreement of Lease dated October 9, 2018 between Georgia Motor Trucking Association, Inc. and Revo Squared, LLC, as amended by First Amendment to Lease Agreement dated November 9, 2021.
3.Agreement of Lease dated May 14, 2019, between Georgia Motor Trucking Association, Inc. and Inhaus Surfaces USA Limited, as amended by Commencement Date Agreement dated December 3, 2019, and by superseding Commencement Agreement dated February 27, 2020.
4.Agreement of Lease dated November 20, 2020, between Georgia Motor Trucking Association, Inc. and Ellis Apex, LLC d/b/a Image 360.
EXHIBIT 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Larry Heaton, certify that:
1. | I have reviewed this quarterly report on Form 10-Q for the three months ended September 30, 2022 of Zomedica Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 14, 2022
| /s/ Larry Heaton |
| Larry Heaton |
| Chief Executive Officer |
| (Principal Executive Officer) |
EXHIBIT 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Ann Marie Cotter, certify that:
1. | I have reviewed this quarterly report on Form 10-Q for the three months ended September 30, 2022 of Zomedica Corp.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 14, 2022
| /s/ Ann Marie Cotter |
| Ann Marie Cotter |
| Chief Financial Officer |
| (Principal Financial and Accounting Officer) |
EXHIBIT 32.1
CERTIFICATION OF
THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002, 18 U.S.C. SECTION 1350
In connection with the Quarterly Report on Form 10-Q of Zomedica Corp. (the “Company”) for the three months ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Larry Heaton, Chief Executive Officer of the Company, and Ann Marie Cotter, Chief Financial Officer of the Company, hereby certify, to the knowledge of the undersigned, pursuant to 18 U.S.C. Section 1350, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 14, 2022
| /s/ Larry Heaton |
| Larry Heaton |
| Chief Executive Officer |
| (Principal Executive Officer) |
Date: November 14, 2022
| /s/ Ann Marie Cotter |
| Ann Marie Cotter |
| Chief Financial Officer |
| (Principal Financial and Accounting Officer) |
This Certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing.
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.